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2. Abbreviations 
 
ACTH adrenocorticotropic hormone 
AMN082 N,N'-dibenzhydryl-ethane-1,2-diamine dihydrochloride 
AMPA (RS)-α-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptor 
BDNF brain-derived neurotrophic factor  
BSA  bovine serum albmine  
cAMP  cyclic adenosine-monophosphate 
CHO cells  chinese hamster ovary cells 
CNS  central nervous system  
CPPG  (RS)-α-cyclopropyl-4-phosphonophenylglycine 
CRF  corticotrophin-releasing factor 
CRFR1  corticotrophin-releasing factor receptor type 1 
CTA  conditioned taste aversion 
FST   forced swim test  
GABA  γ-aminobutyric acid 
GPCRs  G protein-coupled receptors  
GR  glucocorticoid receptor  
GTP  guanosine 5’-triphosphate 
GTPγS  guanosine 5’-O-(3-thiotriphosphate)  
GTPγ[35S] guanosine 5’[gamma-35S] thiotriphosphate  
hmGluR  human metabotropic glutamate receptor 
HPA  hypothalamic-pituitary-adrenal  
5-HT  5-hydroxytryptamine (serotonin)  
5-HT1AR  5-hydroxytryptamine receptor subtype 1A 
IBMX  3-isobutyl-methylxanthine  
i.c.v.  intracerebroventricularly 
iGluRs  ionotropic glutamate receptors  
KA  kainate 
L-AP4   L-amino-4-phosphonobutyric acid  
L-SOP  L-serine-O-phosphate  
LY341495 (2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic 
acid 
[3H]LY341495 (2S)-2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-[2,7-3H]xanth-9-yl) 
propanoic acid 
mGluR  metabotropic glutamate receptor 
MR  mineralocorticoid receptor  
MSOP (RS)-α-Methylserine-O-phosphate 
NMDA  N-methyl-D-aspartate  
PVN  paraventricular nucleus  
rmGluR  rat metabotropic glutamate receptor 
RT-PCR  reverse transcriptase polymerase chain reaction 
SIH  stress-induced hyperthermia  
siRNAs  short interfering RNAs  
SPA  scintillation proximity assay  
TST  tail-suspension test  
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3. Summary 
 
Metabotropic glutamate receptor subtypes (mGluR1 to -8) act as pre- and postsynaptic regulators of 
neurotransmission in the central nervous system. Regulation of neurotransmission via metabotropic 
glutamate receptors has recently been implicated in the pathophysiology of anxiety and stress-
related disorders including depression. Among metabotropic glutamate receptor subtypes, the group 
III metabotropic glutamate receptor subtype 7 (mGluR7) shows the highest evolutionary 
conservation (Flor et al., 1997; Makoff et al., 1996), which suggests that this receptor could play an 
important physiological role. Cryan et al. (2003) have demonstrated that mice with a targeted 
deletion of the gene for mGluR7 (mGluR7-/-) show antidepressant and anxiolytic-like effects in a 
variety of stress-related paradigms, including the forced swim stress and the stress-induced 
hyperthermia tests. Furthermore, the same group has recently developed mGluR7 knockdown using 
siRNA, which further supported the critical role of mGluR7 in anxiety- and stress-related behaviors 
(Thakker et al., 2005). Since the hypothalamic-pituitary-adrenal (HPA) axis regulates stress 
responses, it was investigated in this thesis whether the levels of selected mRNA transcripts and 
endocrine hormones were altered in mGluR7 deficient mice in the HPA axis. Over all, mGluR7-/- 
mice showed only moderately lower serum levels of corticosterone and adrenocorticotropic 
hormone (ACTH) compared to mGluR7+/+ mice. However, strong evidence has been found for up-
regulation of glucocorticoid receptor (GR)-dependent feedback suppression of the HPA axis in mice 
with mGluR7 deficiency: (i) mRNA transcripts of GR were significantly higher in the hippocampus 
of mGluR7-/- animals, (ii) similar increases were seen for 5-HT1A receptor transcripts which are 
thought to be directly controlled by the GR transcription factor and finally (iii) mGluR7-/- mice 
showed elevated sensitivity to dexamethasone-induced suppression of serum corticosterone when 
compared with mGluR7+/+ animals. These results indicate that mGluR7 deficiency causes 
dysregulation of HPA axis parameters which may account, at least in part, for the phenotype of 
mGluR7-/- mice in animal models for anxiety and stress-related disorders. In addition, the data given 
here show that protein levels of brain-derived neurotrophic factor (BDNF) are elevated in the 
hippocampus of mGluR7-/- mice which will be discussed at the latter part of this thesis in the 
context of the stress-resistant phenotype found in those animals. It can be concluded that genetic 
ablation of mGluR7 in mice interferes at multiple sites in the neuronal circuitry and molecular 
pathways implicated in anxiety and stress-related disorders.  
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Taken together, studies with mGluR7 mutant mice and gene knockdown methods in combination 
with behavioral paradigms and the neurochemical studies described above, have strongly indicated 
that mGluR7-selective ligands could be of interest for psychiatric research. To date, there were no 
pharmacological tools selective for mGluR7. The present study shows the characterization of the 
first mGluR7-selective agonist: AMN082 (N,N'-dibenzhydryl-ethane-1,2-diamine dihydrochloride), 
which directly activates receptor signaling via an allosteric site in the transmembrane domain, while 
orthosteric agonists such as L-AP4 and L-glutamate bind to the extracellular region. At transfected 
mammalian cells expressing mGluR7, AMN082 potently inhibits cAMP accumulation and 
stimulates GTPγS binding (EC50-values: 64-290 nM) with agonist efficacies comparable to L-AP4 
and superior to L-glutamate. AMN082 (≤10 µM) failed to show appreciable activating or inhibitory 
effects at other mGluR subtypes and selected ionotropic GluRs. Chimeric receptor studies position 
the binding site of AMN082 in the transmembrane region of mGluR7 and it has been demonstrated 
that this novel allosteric agonist has little, if any, effect on the potency of orthosteric ligands. To my 
knowledge, this study provides the first evidence for full agonist activity mediated by the 
heptahelical domain of family 3 G protein-coupled receptors (GPCRs with mGluR-like structure), 
which opens up new drug discovery opportunities. Further, AMN082 is orally active, penetrates the 
blood-brain barrier, and elevates the plasma stress hormones corticosterone and ACTH in an 
mGluR7-dependent fashion. Interestingly, it has been found that AMN082 induced partial 
internalization of mGluR7 in the hippocampal region, which might lead to functional antagonist 
activity at mGluR7 when tested in vivo.  
The present work suggests that modulation of mGluR7 function may interfere at various levels in 
the physiology of anxiety and stress and that mGluR7-selective ligands may provide a novel 
strategy for the treatment of stress-related disorders. 
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4. Introduction 
 
4.1. Metabotropic glutamate receptors (mGluRs) 
 
Glutamate elicits fast excitatory synaptic responses in the central nervous system (CNS) by 
activating ligand-gated cation channels termed ionotropic glutamate receptors (iGluRs) and plays an 
important role in a wide variety of CNS functions. In addition, in the mid to late 1980s, studies were 
conducted that provided the first evidence for the existence of glutamate receptors that are not 
ligand-gated cation channels but are coupled to effector system through GTP-binding proteins 
(Sladeczek et al., 1985; Sugiyama et al., 1987), termed metabotropic glutamate receptors (mGluRs). 
The wide diversity and heterogeneous distribution of mGluR subtypes could provide an opportunity 
for development of pharmacological agents that selectively target specific CNS systems to achieve 
a therapeutic effect. 
 
4.1.1. mGluR subtypes and classification 
 
 mGluRs are G protein coupled receptors functioning via second messenger pathways to modulate 
activity of glutamatergic circuits. To date, eight mGluR subtypes (designated mGluR1 to mGluR8) 
have been cloned from mammalian brain. These mGluRs are traditionally classified into three 
groups based on their sequence homology, signal transduction mechanisms, and agonist 
pharmacology (Fig. 4.1.; Conn, 2003). The detailed descriptions about pharmacological agents are 
reviewed in Conn (2003) and Schoepp et al., (1999). Group I mGluRs include mGluR1 and 
mGluR5, which couple primarily to Gq, increases in phosphoinositide hydrolysis and are 
selectively activated by 3, 5-dihydroxyphenylglycine (DHPG) and L-quisqualate. Group II mGluRs 
include mGluR2 and mGluR3, which couple to Gi/o and adenylyl-cyclase inhibition followed by 
the decrease of cAMP production. This group is selectively activated by (+)-2-
aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740) and (2S,1’S,2’S)-2-
(dicarboxycyclopropyl)glycine (DCG-IV). Group III mGluRs, which also negatively couple via 
Gi/o to adenylyl-cyclase and inhibit cAMP formation, include mGluR4, mGluR6, mGluR7 and 
mGluR8, and are selectively activated by L-amino-4-phosphonobutyric acid (L-AP4), L-serine-O-
phosphate (L-SOP) and phenylglycine derivatives phosphonophenylglycine (PPG). 
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Figure 4.1. Classification of mGluR family (taken from Conn, 2003).  
The mGluRs are divided into three major groups, on the basis of sequence homology, pharmacological 
profile, and second messenger coupling. 
 
4.1.2. mGluR structure 
 
 mGluRs are members of the G protein coupled receptor (GPCR) family 3 which also includes the 
γ-aminobutyric acid (GABA)B, pheromone, Ca2+-sensing and taste receptors (reviewed in Pin et al., 
2003). The family 3 GPCRs possess a large bi-lobed extracellular N-terminal domain analogous to 
the “Venus’ flytrap” model, which has been demonstrated by both site-directed mutagenesis and X-
ray crystallography. This N-terminal bi-lobed domain is linked via an extracellular cystein-rich 
region to the seven transmembrane domain which is the common structural domain of all known 
GPCRs. The “Venus’ flytrap” domain contains the L-glutamate binding site and induces a 
conformational change that results in the closure of the flytrap and propagation of the signal 
through the transmembrane domain (Fig. 4.2.; Spooren et al., 2003). The C-terminus is intracellular 
and plays an important role in the regulation of receptor activity and targeting through interaction 
with proteins including calmodulin, the Homer proteins and PICK1 (Dev et al., 2001; El Far and 
Betz, 2002; Pin et al., 2003). mGluRs are dimeric proteins and functional mGluRs are thought to 
comprise homodimers stabilized by not only an intersubunit disulfide bond but also hydrophobic 
interactions. The dimeric ligand-binding region of mGluR adopts multiple conformations, where the 
activated forms of the dimer are in equilibrium with other states (Kunishima et al., 2000). When 
mGluRs are not activated, the bi-lobed extracellular domains of the homodimer exist far from each 
other, which constitutes an open conformation. Binding of an agonist makes the dimer closer and it 
adopts a closed conformation. Recently it was shown that while a single molecule agonist binding 
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to one of the homodimer is sufficient to partially activate the receptor, full receptor activation 
requires agonist binding to both sides of the homodimer (Kniazeff et al., 2004). In addition, Suzuki 
et al., (2004) has demonstrated the negative co-operativity of glutamate binding in the dimeric 
mGluRs.  
 
          
Figure 4.2. A schematic representation of the dimeric prototypical form of mGluRs (taken from 
Spooren et al., 2003). 
The large N-terminal extracellular domain contains the L-glutamate binding site. The homodimer is 
stabilized by non-covalent binding and a disulfide bond. Upon agonist binding, the flytrap closes and the 
agonist is thought to stabilize the closed conformation by making bonds with residues of both lobes.                   
 
4.1.3. mGluR localization and function 
 
 4.1.3.1. Group I mGluRs 
 Distribution of immunoreactivity for mGluR1 was observed extensively throughout the rodent 
brain (reviewed in Spooren et al., 2003), with especially abundant levels in the olfactory bulb, the 
thalamus, the cerebellum and certain regions of the hippocampus. In the hippocampus, mGluR1 was 
strongly expressed in dendritic fields of the dentate gyrus and the CA3 area, but not in the CA1 
region. mGluR5 was highly expressed in the accessory olfactory bulb, the hippocampus, the input 
regions of the basal ganglia (striatum and nucleus accumbens) and the lateral septum. Group I 
mGluRs are mainly localized to somatodendritic domains of neurons and have shown to be 
expressed preferentially at the periphery of the postsynaptic densities of asymmetrical synapses 
(Lujan et al., 1996), although there is some anatomical and biochemical evidence for presynaptic 
localization (van den Pol, 1995). Within the CNS, Group I mGluRs play an important role in 
regulating fast synaptic transmission mediated by glutamate, and are involved in synaptic plasticity 
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phenomena, including long term potentiation (LTP) and long term depression (LTD). For example, 
mice lacking mGluR1 or mGluR5 have been reported to have impaired cerebellar LTD and 
hippocampal LTP (Aiba et al., 1994; Conquet et al., 1994) or hippocampal CA1 LTP (Lu et al., 
1997), respectively. In addition, an mGluR5 specific antagonist caused impaired LTP in the lateral 
amygdala (Rodrigues et al., 2002). Furthermore, group I mGluRs have been shown to interact with 
NMDA receptors bi-directionally (Alagarsamy et al., 2005; Heidinger et al., 2002).  
 
  4.1.3.2. Group II mGluRs 
 mGluR2 is expressed largely in extrasynaptic sites remote from the active zone in neuronal 
terminals. Moderate to high expression of this receptor is found in the neocortex, various limbic 
cortical regions including the hippocampus and the amygdala (Ohishi et al., 1998; reviewed in 
Spooren et al., 2003). Immunoreactivity for mGluR3 was found extensively in the rodent brain with 
intense levels in the neocortex, the hippocampus and the lateral and the basolateral amygdaloid 
nuclei. mGluR3 is localized in both pre- and postsynaptic elements of neurons, as well as more 
widely in glial cells (Tamaru et al., 2001). The vast majority of mGluR3 at presynaptic site was 
found in extrasynaptic membrane. Therefore it is conceivable that group II mGluRs might be 
activated by spillover glutamate from distant synapses on the same or other presynaptic elements 
(Vogt and Nicoll, 1999) and function as sensors for glutamate spill over. As mentioned above, 
Group II mGluRs are coupled to the inhibition of the cAMP cascade in neuronal and glial cells, but 
also linked to rapid-onset regulation of various channels including calcium channels and G protein 
coupled inwardly rectifying K+ channels depending on neuronal cell types (reviewed by Anwyl, 
1999). 
 
  4.1.3.3. Group III mGluRs 
Strong mGluR4 immunoreactivity was observed in the cerebellum and in the globus pallidus, 
although it was generally weak in the hippocampus. Electron microscopic studies of mGluR4 
revealed presynaptic localization, as well as exclusive postsynaptic localization in the retina 
(reviewed in Shigemoto and Mizuno, 2000). It has been reported that mice lacking mGluR4 had 
impaired cerebellar synaptic plasticity and motor performance (Pekhletski et al., 1996). mGluR6 
expression is restricted to the postsynaptic, dendritic part of retinal ON bipolar cells. Knockout 
animals of this receptor have been reported to have visual acutely deficits (Masu et al., 1995; Takao 
et al., 2000). Distributions of two alternative splice forms of mGluR7 (mGluR7a and mGluR7b) 
were examined in the CNS by using variant-specific antibodies. The distribution of mGluR7b is 
more limited than mGluR7a which is widely distributed throughout the brain with a high level of 
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expression in the locus coeruleus and the limbic regions. mGluR7b is relatively highly expressed in 
the limbic regions and the globus pallidus. mGluR7 is exclusively detected in the presynaptic active 
zone in glutamatergic terminals and is believed to function as an autoreceptor activated by 
glutamate released from the active zone where it is located. In addition, mGluR7 is also highly 
expressed in some GABAergic terminals (Somogyi et al., 2003) and therefore heterosynaptic 
interaction should be present. Moreover, compared to other mGluR subtypes, mGluR7 has a much 
lower affinity for glutamate (mM) which is indeed thought to be the concentration range reached at 
presynaptic release sites of glutamate; consistent with the localization profile of this receptor. 
mGluR8 shows a much more restricted distribution compared to that of mGluR4 or mGluR7. 
Expression of mGluR8 was observed in the olfactory system, the neocortex, the limbic cortex 
including the hippocampus and the amygdala. Electron microscopically, mGluR8 was largely 
observed on the axon terminals. Especially in several regions of the hippocampus it was found in 
the active zone of both asymmetrical and symmetrical synapses where mGluR8 may regulate 
glutamate release as an autoreceptor or GABA release heterosynaptically (Ferraguti et al., 2005). 
 
4.1.4. The potential role of mGluRs in nervous system disorders: focus on Group III mGluRs 
 
Because of their ubiquitous distribution, mGluRs can contribute to a wide variety of functions in the 
CNS. Because of the wide diversity and heterogeneous distribution of mGluR subtypes, there is an 
opportunity for developing highly selective drugs to affect specific CNS functions. Because the 
focus of this thesis is mGluR7, only disorders in which group III mGluRs are thought to be 
involved are addressed. Since group III mGluRs with the exception of mGluR6 which is exclusively 
expressed in the retina are predominantly located presynaptically, activation of these receptors 
might predominantly result in a reduction of glutamatergic activity, or even GABAergic 
transmission as heteroautoreceptors. It has therefore been hypothesized that group III mGluRs 
might be targets for following disorders even though there are few pharmacological tools with the 
receptor subtype selectivity ideal for testing the significance of the subtypes of group III mGluRs. 
 
4.1.4.1. Epilepsy 
Recent studies pointed to mGluRs as potential targets for the treatment of epilepsy. Group I mGluR 
agonists were shown to be convulsants, while the group II and III mGluR agonists showed 
anticonvulsant effects (Moldrich et al., 2003). For example, group III mGluR agonists (reviewed in 
Yang, 2005), L-AP4, L-SOP, PPG and (S)-3,4-dicarboxyphenylglycine [(S)-3,4-DCPG] blocked 
seizures in several rodent models and the prolonged anticonvulsant effect of L-SOP has been 
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reported to be possibly induced by mGluR4 and/or mGluR7 up-regulation (Yip et al., 2001). 
Furthermore, an mGluR4 selective agonist protected against several kinds of seizures following its 
intracerebroventricular (i.c.v.) administration (Chapman et al., 2001), although Snead et al., (2000) 
showed that the mGluR4 knockout mice were markedly resistant to GABAAR antagonists-induced 
absence seizures. Taken together, the group III mGluRs can most probably counteract the epileptic 
activity possibly via regulating enhanced glutamatergic excitability observed in epilepsy. 
 
4.1.4.2. Parkinson’s disease 
Many recent studies have revealed that members of the mGluR family are differentially distributed 
and function in several basal ganglia nuclei which regulate motor function and which is involved in 
the pathology of the movement disorder, Parkinson’s disease. In acute and chronic models of 
Parkinson’s disease, L-AP4 produced therapeutic benefits with decreased GABAergic transmission 
at the striatopallidal synapse where increased GABAergic inhibition is thought to play an important 
role in motor dysfunction (Valenti et al., 2003). Consistent with this, mGluR4 allosteric modulation 
with mGluR4 selective potentiators also produced antiparkinsonian effect in a rodent model of 
Parkinson’s disease (Marino et al., 2003). 
 
4.1.4.3. Anxiety and Stress-related disorders 
Various mGluR subtypes specifically modulate excitability within brain structures thought to be 
involved in anxiety and stress-related illness. Besides the anxiolytic-like effects of Group I 
antagonists and Group II agonists, recent works point to the potential roles of group III mGluRs in 
psychiatric disorders (reviewed in Swanson et al., 2005). For instance, intrahippocampal injection 
of L-SOP showed anxiolytic-like effects in the Vogel conflict drinking test and i.c.v. injection of 
PPG demonstrated antidepressant-like stress-resistant action in the forced swim test (Palucha et al., 
2004). In addition, knockout animal studies indicate the significance of the group III mGluRs to 
anxiety and stress-related pathways. mGluR7 knockout mice have shown the impairment of two 
distinct amygdala-dependent behavioral paradigms; the fear-mediated freezing response and the 
conditioned taste aversion test, without altering their pain threshold nor abnormalities in taste 
preference (Masugi et al., 1999). Furthermore, these knockout animals have demonstrated 
anxiolytic-like and stress-resistant phenotype in the elevated plus maze, the staircase test, the light-
dark box test, the stress-induced hyperthermia model, the tail suspension test and the forced swim 
test (Cryan et al., 2003). By contrast, mGluR8 knockout mice have been shown to increase 
measures of anxiety-like behavior in the open field and the elevated plus maze (Duvoisin et al., 
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2005). Taken together, it appears that group III mGluRs have various roles in anxiety and stress-
related disorders. 
 
4.2. Psychiatric disorders: focus on anxiety and depression 
 
Psychiatric disorders are serious and debilitating medical conditions with high levels of morbidity 
and mortality. Depression and anxiety represent some of the most common health problems 
worldwide (reviewed in Cryan and Holmes, 2005). Of greater concern is that suicide, which is one 
of the devastating consequences of mental disruption, is now the third largest cause of death among 
young adults in Western countries and was indeed the largest cause of death in 2004 among 
Japanese young people from twenty to forty-five years of age. 
 
4.2.1. Molecular changes: focus on HPA axis 
 
All living organisms tend to maintain a dynamic equilibrium called homeostasis (reviewed in 
Stratakis and Chrousos, 1995). Under stressful situations, this equilibrium is often disturbed and our 
bodies try to rebuild the homeostasis with some stress responses. These stress responses should be 
activated rapidly when they are needed and should be efficiently terminated when the stress-causing 
situation ends. If the stress responses are inappropriate or immoderately and prolonged, mental 
illnesses may result. The stress responses are composed of many molecular and cellular changes, 
and the activation of the hypothalamic – pituitary – adrenal (HPA) axis plays a pivotal role. 
Dysregulation of the HPA axis is thought to play a central role in the pathophysiology of anxiety 
and depressive disorders (Barden, 2004; de Kloet et al., 2005). During stress, the synthesis of 
corticotrophin-releasing factor (CRF) in the hypothalamic paraventricular nucleus (PVN) increases 
and when CRF is released and reaches the anterior pituitary gland, it promotes the release of 
adrenocorticotropic hormone (ACTH), which, in turn, induces the synthesis and release of 
glucocorticoids (primarily corticosterone in rodents and cortisol in humans) from the adrenal cortex. 
CRF is also known to play a role in the activation of the sympathetic nervous system. 
Glucocorticoid effects are mediated by two types of nuclear receptors; the mineralocorticoid 
receptor (MR) and the glucocorticoid receptor (GR), the latter having less affinity to glucocorticoid 
than MR. Whereas disturbance of homeostasis is prevented by MR-mediated processes, its recovery 
is facilitated via GR that requires stress levels of glucocorticoids and it appears that the main 
function of GR in the brain is to suppress stress-induced hyperactivity of the HPA axis at the level 
of the PVN, the anterior pituitary, but also at the hippocampal level (reviewed in Barden, 2004). 
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Since MR and GR are nuclear receptors, they can regulate the transcription of genes. In the later 
recovery phase, GR monomers are capable of interacting with transcription factors and repress 
stress-induced responses (De Kloet, 2004).  
In addition, accumulating data suggest that the serotonin (5-HT) system and the HPA axis have 
complex inter-relationships (reviewed in Porter et al., 2004), which is consistent with the clear 
understanding that dysfunction of serotonergic neurotransmission is associated with several mood 
disorders including depression and anxiety. In particular, the 5-HT1A receptor has received a great 
deal of attention in recent years because this receptor is very susceptible to modulation by stress and 
HPA axis activation and is well known to play an important role in the pathophysiology of mood 
disorders (reviewed in Cryan and Leonard, 2000).  
 Furthermore, recent evidences point also to an important role for the neurotrophin brain-derived 
neurotrophic factor (BDNF) in both the pathophysiology of mood disorders and in the therapeutic 
effects of antidepressants (reviewed in Hashimoto et al., 2004). Pre-clinical studies have shown that 
the infusion of BDNF into the midbrain has an antidepressant-like influence on animal models of 
depression and clinical studies have demonstrated that serum levels of BDNF in drug-naive patients 
with depressive disorders are significantly decreased when compared with normal controls. 
  
4.2.2. Stress models in rodents 
 
Exposure to excessive stress has been thought to be one of the main factors to make individuals 
susceptible to depression and the inability to cope effectively with stress is often regarded as a 
hallmark in depressed patients. Therefore, many rodent models for assessing depression-like stress-
related behavior are based on this aspect and involve exposure to stressful situations (reviewed in 
Cryan and Holmes, 2005). Among those, probably the most studied and known model is the forced 
swim test (FST). In the FST, rodents are placed in an inescapable cylinder filled with tepid water. 
They will initially try to escape with vigorous movements, but then within minutes they will 
develop immobile postures. Another well-known model is the tail-suspension test (TST), in which 
mice hung upside-down by their tails will exhibit passive immobility in response to this inescapable 
stress after minutes of fruitless struggling. However, the TST has also been reported to have wide 
strain differences (Liu and Gershenfeld, 2001) and is often used in addition to the FST. The other 
reason why these tests are regarded as rodent models for depression in humans is that 
administration of various clinically effective antidepressants to rodents before the test leads to 
longer periods of escape-oriented behaviors compared to vehicle-treated rodents. Therefore these 
animal models have also been used as rapid screening assays for searching new antidepressants.  
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Anxiety models were also developed based on the effects of clinically effective anxiolytics. 
However, it should be noted that the state of anxiety itself is indeed a normal response that 
everybody has, as distinct from depression. The hallmark of anxiety is marked, persistent and 
excessive or unreasonable fear which is enough to affect everyday life (reviewed in Cryan and 
Holmes, 2005). Many animal models of anxiety disorders are therefore linked to the natural 
behavioral patterns of rodents; small rodents have an innate aversion to exposed and brightly open 
areas presumably because of their instincts to hide from enemies, on the other hand, they are also 
foraging species. Based on the conflicts between the tendency to explore a novel environment and 
aversion to bright spaces, many behavioral tests are regarded as models of anxiety in humans, such 
as the elevated plus maze, the elevated zero maze, the open field test, the light-dark box test and the 
staircase test. Another innate response of rodents in stress-related behavior is the increase in core 
body temperature, which is another hallmark of the stress response in mammals. The stress-induced 
hyperthermia (SIH) test which quantifies the degree of hyperthermia elicited by a short mild stress 
is technically easier to be done compared to other models, since measuring rectal temperature itself 
can be the stressor. Clinical anxiolytics reduced the degree of SIH and the innate aversion in 
ethological tests. 
Furthermore, since cognitive disturbances are also seen in patients with depression or anxiety 
disorders, rodent models for studying emotional cognition have been also developed (reviewed in 
Cryan and Holmes, 2005). Pavlovian fear-conditioning tasks are one of the representative models; 
rodents are exposed to a harmless neutral stimulus associated with an innate aversive stimulus and 
after these repeated pairings, they develop fear responses only with the harmless neutral stimulus. 
Another conditioned learning test is conditioned taste aversion (CTA). In this test, rodents learn the 
association of a novel flavor with delayed malaise, such as that induced by lithium chloride and 
after a conditioning trial, they reduce their preference of the flavored foods associated with that 
aversive response.  
Although we should be careful to translate animal models into human disorders like most of the 
other research tools, they can be useful in preclinical psychiatric research. 
 
4.3. Behavioral effects of mGluR7 mutant animals in stress-related paradigms 
 
mGluR7 is the most highly conserved receptor of all mGluR subtypes across different mammalian 
species (Flor et al., 1997; Makoff et al., 1996). Therefore, it might be conceivable that this receptor 
plays an important role in mammals. Since mGluR7 is abundant in brain regions that are known to 
be critical for the manifestation of anxiolysis and antidepressant action, such as the hippocampus, 
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the amygdala, and the locus coeruleus (Kinoshita et al., 1998), this receptor has attracted attention 
in psychiatric research. However, since there were no pharmacological tools selective for mGluR7, 
research on mGluR7 to date has been done with mGluR7 gene-mutated animals. 
 
4.3.1. mGluR7 knockout animal studies 
 
Mice lacking mGluR7 have deficits in amygdala-dependent behaviors (fear response and 
conditioned taste aversion), but show no alterations in locomotor activity nor pain sensitivity 
(Masugi et al., 1999). Electrophysiological analysis in mGluR7 knockout (mGluR7-/-) mice further 
suggests that this receptor modulates short-term synaptic plasticity in the hippocampus (Bushell et 
al., 2002). Moreover, mGluR7 ablation in mice has been demonstrated to be associated with 
changes in animal behavioral paradigms and predictive of antidepressant and anxiolytic actions 
which suggest that drugs acting at mGluR7 may provide novel treatments for psychiatric disorders 
such as depression and anxiety (Cryan et al., 2003). These tests including the FST (Fig. 4.3.A.), the 
TST (Fig. 4.3.B.), the light-dark box test (Fig. 4.4.A.), and the SIH (Fig. 4.4.B.), all involve 
observing the animal’s response to a novel stressful situation. The data suggest that mGluR7 may 
play a role in the stress response to aversive stimuli. 
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Figure 4.3. Antidepressant-like activity in mGluR7-/- mice (taken from Cryan et al., 2003). 
(A) mGluR7-/- mice had a much lower immobility score than its littermate mGluR7+/+ mice in the forced 
swim test. (B) Similarly, mGluR7-/- mice had a much lower immobility score than mGluR7+/+ mice in the tail 
suspension test. *p < 0.05, significantly different from mGluR7+/+ mice.                
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Figure 4.4. Anxiolytic-like activity in mGluR7-/- mice (taken from Cryan et al., 2003). 
(A) mGluR7-/- mice had a markedly higher number of transitions between the dark and light compartments 
throughout the 10 min of the test compared to its littermate mGluR7+/+ mice in the light-dark box test. (B) 
mGluR7-/- mice had a much lower stress-induced hyperthermia (SIH) than mGluR7+/+ mice. *p < 0.05, 
significantly different from mGluR7+/+ mice. 
 
 
4.3.2. mGluR7 knockdown animal studies 
 
In studies with gene knockout animals we always have to consider whether the readouts come from 
the direct consequences of genetic ablation or developmental compensations. To lessen the 
possibility of developmental compensations, there are several emerging techniques. One of those is 
the RNA interference (RNAi) technique. RNAi is a cellular surveillance mechanism found in nature, 
which responds to double-strand RNA (dsRNA) by destroying cytoplasmic mRNAs containing 
sequences homologous to the dsRNA trigger (Fire et al., 1998). However, when dsRNA is 
introduced in mammalian cells, it can induce an undesirable interferon response leading to cell 
death. Short interfering RNAs (siRNAs) that mimic the cleavage products of dsRNA in mammalian 
cells produce sequence-specific gene-silencing in these cells without such an undesirable response 
(Caplen et al., 2001). Thakker et al., (2004) established siRNA-induced knockdown in adult brain in 
vivo. Recently, by using this method, Cryan and his colleagues have developed and tested mGluR7 
knockdown mice in several behavior models, including the light-dark box test and the SIH 
(unpublished data; but see Thakker et al., 2005). The knockdown of mGluR7 in adult mice brains 
results in the stress-resistant phenotype very similar to that observed in mGluR7 knockout animals. 
Interestingly, the level of mGluR7 knockdown was only significant in a few brain regions such as 
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the amygdala and the hippocampus. These results indicate that moderate knockdown of mGluR7 
results in reduced anxiety-like and stress-related behaviors confirming the phenotype observed in 
mGluR7 knockout mice and further supporting an important role of mGluR7 in psychiatric diseases.  
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 4.4. Scientific questions addressed in this thesis 
 
Given that mGluR7 knockout mice have a phenotype that is indicative of an altered behavioral 
response to stress, which is further supported by mGluR7 siRNA knockdown studies the hypothesis 
was that mGluR7 affects stress-related systems at different levels. Since the neurophysiological 
mechanisms underlying the phenotype of mGluR7 knockout mice were not yet clarified, this thesis 
explores representative molecular targets and physiological mechanisms that are involved in stress 
regulation of the mammalian brain. 
Moreover, in spite of cumulative reports for the importance of mGluR7 the research regarding 
mGluR7 still lags behind that of other mGluR subtypes because of the lack of selective 
pharmacological tools. From this point of view, it would be very desirable to have mGluR7-
selective pharmacological tools. Since mGluRs can play a role in the fine tuning of 
neurotransmission and might be better targets with less side-effects compared to the targets of 
current treatments for psychiatric disorders, the discovery of mGluR subtype selective tools might 
result in scientific and possibly clinical advances. The second part of this thesis characterizes the 
first mGluR7 selective agonist.  
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5. Materials and Methods 
 
5.1. Animals 
 
mGluR7-/- mice were generated as described previously from E14 (129/Ola) embryonic stem cells 
(Sansig et al., 2001). The breeding, genotyping and housing animals were done by a central animal 
facility at Novartis. Larger age-matched groups of mGluR7-/- and mGluR7+/+ mice were generated 
using a specific pathogen-free (SPF) breeding colony of 30 F14, B6-mGluR7+/- males mating with 
60 - 90 F14, B6-mGluR7+/- females. All the mice in the studies reported here carried wild-type or 
mutant mGluR7 alleles on a fourteenth generation C57BL/6 genetic background. Mice were 
weaned at the age of 3 weeks, when tail biopsies were also taken for genotyping. Subsequently, 
genotyped mice were moved to a non-SPF conventional facility in which male animals were used 
for experiments at the ages of 3 - 9 month. Housing was at room temperature, in a 12 h light:dark 
cycle, with lights on at 6:00 a.m. Male animals were used in all experiments. Food pellets and tap 
water were available ad libitum unless stated otherwise. Following decapitation of mice (mGluR7-/- 
and mGluR7+/+ mice in a randomized order), bloods were collected and brains were immediately 
removed and frozen on dry-ice and stored at –80 °C. All animal experiments were subject to 
institutional review and conducted in accordance with the Veterinary Authority of Basel-Stadt, 
Switzerland.   
5.2. in vivo AMN082 administration 
 
Male mGluR7-/- or littermate mGluR7+/+ mice (C57BL/6 genetic background) were injected orally 
(p.o.) with either vehicle or 1 - 6 mg/kg N,N'-dibenzhydryl-ethane-1,2-diamine dihydrochloride 
(AMN082; synthesized by Joachim Nozulak and Silvio Ofner within Novartis Pharma AG). One 
hour later, those mice were investigated for each purpose. 
5.3. Blood sample collection 
 
5.3.1. Blood sample collection for basal and stress-induced conditions 
In order to investigate the effects of mGluR7-/- mice on basal corticosterone and ACTH levels, male 
mGluR7-/- (n = 10 per gender) and littermate mGluR7+/+ (n = 10 per gender) mice were decapitated 
and the blood was collected. Two batches of mice were sacrificed, one between 7:00 and 8:00 a.m. 
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and the other between 5:00 and 5:30 p.m. For the stress-induced hormone levels, male mGluR7-/- 
and littermate mGluR7+/+ mice were subjected to swim stress (6 min) into plexiglass cylinders (24 
cm tall x 21 cm in internal diameter) filled with water (23 – 25 °C). Mice were decapitated 5 min or 
90 min after the stress session (n = 10 per genotype and per time point) in another room and the 
blood was collected between 8:00 and 11:00 a.m. Simultaneously, non-stressed male mice (n = 10 
per genotype) were sacrificed, which constituted control groups. All of the processes mentioned 
above were carried out by Hugo Buerki and Cedric Mombereau. 
 
5.3.2. Blood sample collection following Dexamethasone suppression test 
The Dexamethasone suppression test was carried out essentially as described by Groenink and 
colleagues (2002). Male mGluR7-/- and littermate mGluR7+/+ mice were injected subcutaneously 
(SC) with saline, 0.03 or 0.1 mg/kg dexamethasone-21-phosphate disodium salt (Fluka, Buchs, 
Switzerland). Six hours later, mice were decapitated rapidly (within 30 sec after first touching the 
cage) in an adjacent room, and trunk blood was collected (n = 10 per genotype). All of the 
processes mentioned above were carried out by Hugo Buerki and Cedric Mombereau. 
 
5.3.3. Blood sample collection following AMN082 injection 
AMN082 administration was done as mentioned above. One hour later, mice were decapitated 
rapidly (within 30 seconds after first touching the cage; mGluR7-/- and mGluR7+/+ mice in a 
randomized order) and trunk blood was collected (n ≥ 9 per genotype). 
 
5.4. Hormone measurement 
 
Plasma corticosterone and ACTH concentrations were measured using commercially available 
radioimmunoassay kits (ICN Biomedicals, Costa Mesa, CA, USA). The inter- and intra-assay 
coefficients of variability for ACTH and corticosterone were similar to the manufacturer’s reported 
values with a detection limit of 5 - 10 pg/ml.  
 
5.5. Extraction of BDNF from tissues 
 
Various brain regions were dissected, weighed, collected on dry ice, and stored at –80 °C, or 
dissected as soon as the frozen brains started to thaw and weighed. The extraction of BDNF was 
performed basically as described previously (Kolbeck et al., 1999) and briefly mentioned as below. 
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20 - 40 vol/wt of extraction buffer [0.05 M sodium acetate, pH 4.0, 1.0 M sodium chloride, 1 % 
(vol/wt) BSA (A-9418 of Sigma, Buchs, Switzerland), 1 % Triton X-100, protease inhibitor cocktail 
tablets (Cat.No. 1 836 153, Roche, Rotkreuz, Switzerland)] was added and the tissues sonicated to 
homogeneity. The homogenates were kept on ice for 1 h and the sonication repeated three times. 
The homogenates were centrifuged (15 min, 105 g), the supernatants (first extraction) collected, and 
the pellets resuspended in 20 - 40 volumes of extraction buffer. After another centrifugation (15 min, 
105 g), the supernatants were collected (second extraction) and the pellets resuspended in 20 - 40 
volumes of extraction buffer. After another centrifugation (15 min, 105 g), the supernatants were 
collected again (third extraction). 
 
5.6. BDNF immunoassay 
 
Quantification of BDNF from tissue extracts was carried out essentially as described by Kolbeck et 
al. (1999). Plates (MaxiSorp plates, Nunc, Rosklide, Denmark) were coated with carbonate buffer, 
pH 9.7 containing 400 ng per well of biotinylated first anti-BDNF antibody (courtesy of Yves A. 
Barde, University of Basel, Switzerland) overnight at 4 °C and incubated with blocking buffer 
[Phosphate-buffered saline (PBS), 2 % BSA, 0.1 % Triton X-100] for 1 h at room temperature. 
Standard amounts of BDNF were diluted in extraction buffer (0.1 - 6.25 ng/ml), and 25 µl per well 
of each concentration was applied. 25 µl per well of the extraction buffer alone (negative control) 
was used to check background activity. Similarly, 25 µl per well of different dilutions of the tissue-
extract supernatants was added to the wells. Subsequently, 175 µl per well of incubation buffer [0.1 
M potassium/sodium phosphate, pH 8.0, 1 % BSA, protease inhibitor cocktail tablets (Cat.No. 1 
836 153, Roche, Rotkreuz, Switzerland)] containing 100 mU/ml peroxidase (POD)-conjugated anti-
BDNF antibody (courtesy of Yves A. Barde, University of Basel, Switzerland) was applied and 
incubated overnight at 4 °C. Plates were washed with washing buffer [Phosphate-buffered saline 
(PBS), 0.1 % Triton X-100] 3 times and incubated with 200 µl per well of the BM blue POD 
substrate (Roche, Rotkreuz, Switzerland) for 30 min at room temperature. The reaction was stopped 
with 50 µl of 1 M sulfonic acid per well, and the intensity of the reaction product was measured in a 
luminometer at 490 nm. BDNF levels in tissue extracts were determined by comparison with the 
standard curve. 
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5.7. “Real-Time” Reverse Transcriptase (RT) PCR assays 
 
Brain regions per mice were disrupted (2 x 2 minutes at 20 Hz) by using a Mixer Mill MM 300 
(Retsch GmbH & Co. KG, Haan, Germany). Total RNA was isolated from disrupted brain tissue 
using the commercially available “Absolutely RNATM” RT-PCR Miniprep Kit (Stratagene, 
Amsterdam, The Netherlands). The quantity of RNA was determined by optical density (OD) 
measurement using a NanoDrop®ND-1000 Spectrophotometer. To remove traces of genomic DNA 
contamination, an aliquot of 400 ng total RNA was digested with RNAse-free DNAse I (RNAse-
Free DNase Set, Qiagen, Hilden, Germany). The enzyme was inactivated by addition of EDTA and 
by heating up to 65 °C. DNAse I-treated total RNA was reverse transcribed into cDNA by random 
priming using StrataScriptTM Reverse Transcriptase (Stratagene, Amsterdam, The Netherlands) at 
42 °C for 60 minutes. Primers and probes were designed with the aid of the Primer Express 
software (Version 1.0; Applied Biosystems, Foster City, CA, USA) by Erika Lötscher and 
Genevieve Kuntzelmann. The probes were labeled at the 5’ end with the reporter fluorophore 6-
carboxyfluorescein (FAM) and at the 3’ end with the quencher 6-carboxytetramethyl-rhodamine 
(TAMRA). Primers and probes were synthesized commercially (Microsynth, Balgach, Switzerland). 
The sequences of the primer pairs and probes were as shown in the table of sequences (below). 
“Real-Time” RT PCR (TaqMan®) assays were performed using the qPCRTM Mastermix 
(Eurogentec, Seraing, Belgium) on an ABI Prism® 7700 sequence Detection System (Applied 
Biosystems, Foster City, CA, USA). In all assays for the target genes, primers and probes were used 
at 300 nM and 175 nM, respectively. Assays for the internal control gene 18S rRNA were 
performed by using the “18S Genomic Endogenous Control Kit” (Eurogentec, Seraing, Belgium). 
Relative levels of the target mRNA are reported after normalization to 18S rRNA, which was also 
detected by “Real-Time” RT PCR. The normalized raw data, representing the average values of two 
independent determinations, were analyzed by using the “comparative CT method”, as described in 
details by Livak and Schmittgen, (2001). 
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Table of Sequences: Primers and probes used in “Real-Time” RT PCR assays for assessing 
relative expression profiles of target genes 
 
Gene 
product 
GenBank/RefSeq 
Accession Number 
Sequences of primer and probe 
BDNF BC034862 5'-CCA TAA GGA CGC GGA CTT GT-3' 
5'-GAG GCT CCA AAG GCA CTT GA-3' 
5' FAM-CAC TTC CCG GGT GAT GCT CAG CA-TAMRA 3' 
CRF AY128673 5'-AGC AGT TAG CTC AGC AAG CTC A-3' 
5'-GGC CAA GCG CAA CAT TTC-3' 
5' FAM-TCC CGA TAA TCT CCA TCA GTT TCC TGT TGC T-TAMRA 3' 
CRF1 X27305 5'-TCC GGT GCC TGA GAA ACA TC-3' 
5'-CGT GGC GTT GCG TAG GA-3' 
5' FAM-TCC ACT GGA ACC TCA TCT CGG CTT TC-TAMRA 3' 
GR X04435 5'-CGG GAC CAC CTC CCA AA-3' 
5'-CCC CAT AAT GGC ATA CCG AA-3' 
5' FAM-TCT GCC TGG TGT GCT CCG ATG AAG-TAMRA 3' 
5-HT1A  NH012585 5'-GCT CAT GCT GGT TCT CTA CGG-3' 
5'-GAC AGT CTT GCG GAT TCG GA-3' 
5' FAM- CGC ATC TTC AGA GCC GCA CGC-TAMRA 3' 
mGluR7 NM000844 5'-GCG CTC GAA CAG TCG CTT A-3' 
5'-CGC ACG TCG GAG GTG TC-3' 
5' FAM-TTT CGT CCA GGC GCT CAT CCA GA-TAMRA 3' 
MR XM356093 5'-TGG ATG TGG TTG GAT GTA GGG-3' 
5'-TCT ACC TGT TGC AGC GCT TG-3' 
5' FAM-CCA CGA CAA CCC TGC TGC GGA G-TAMRA 3' 
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5.8. Stable cell lines 
 
Generation, culture and pharmacological characterization of stable cell lines for mGluR1b, mGluR2, 
mGluR3, mGluR4, mGluR5a, mGluR6, rmGluR7a, hmGluR7b, NMDAR1A/2A, NMDA1A/2B 
and GluR3i have been described (Flor et al., 1995; Flor et al., 1997; Gasparini et al., 1999a; 
Gasparini et al., 1999b; Knopfel et al., 1995; Maj et al., 2003). Cell lines for rmGluR7a and 
rmGluR2 were generous gifts from Shigetada Nakanishi at Kyoto University, Japan.  
 
5.9. Construction of chimeric receptors and corresponding cell lines 
 
cDNAs encoding wild-type hmGluR6 and hmGluR7b were described previously (Flor et al., 1997; 
Weng et al., 1997). cDNAs encoding chimeric hmGluR6/7b and hmGluR7/6 proteins were 
constructed by Natacha Stoehr, using a PCR overlap extension approach (Horton et al., 1989): the 
mGluR6/7b construct contains 570 amino acids derived from the N-terminal extracellular region of 
mGluR6 and the remaining C-terminal portion of mGluR7b, comprising the entire transmembrane 
region; mGluR7/6 is essentially the reverse chimera with the fusion point at amino acid 575. The 
four constructs were used to generate stably transfected cell lines by Flp recombinase-mediated 
integration (Flp-InTM T-RExTM Core Kit; Invitrogen Ltd., Paisley, UK) in Chinese Hamster Ovary 
(CHO)-C4 cells (Novartis Pharma AG, Basel, Switzerland), which contain a single Flp recognition 
target (FRT)-site; the identical host was used for all the four new cell lines. 
 
5.10. Membrane preparation and GTPγ[35S] binding assays 
 
Membranes were prepared from transfected cells using essentially the protocol described previously 
(Lazareno and Birdsall, 1993; Gasparini et al., 1999b). The culture of transfected mGluR2-, 
mGluR3-, mGluR4-, mGluR6-, mGluR7a-, mGluR7b-, mGluR6/7b-, or mGluR7/6-expressing cells 
was expanded to seed 30 - 60 cells per 15 cm dishes. The cells were harvested when they reached 
80 - 95% confluency followed by homogenization in buffer A (20 mM HEPES, 10 mM EDTA, pH 
7.4) using a Polytron and centrifugation at 39'000 g at 4 °C for 20 min. The pellet was resuspended 
in buffer B (20 mM HEPES, 0.1 mM EDTA, pH 7.4), homogenized using a Polytron and re-
centrifuged at 39'000 g at 4 °C for 20 min. The pellet was resuspended in buffer B at a protein 
concentration of 2 to 3 mg/ml, aliquoted, snap frozen on dry ice and stored at -80 °C. Membrane 
fractions were diluted in assay buffer (20 mM HEPES, 10 mM MgCl2, 100 mM NaCl, 2 mM EGTA, 
 27
20 µM GDP, pH 8.0), homogenized briefly using a Polytron and incubated for 10 min at 30 °C. 
Following that pre-incubation, assay-mixtures were prepared in 96-well microtiter plates. After 
optimization of various parameters, the composition of the assay mixtures in a final volume of 200 
µl per well was as follows: 20 mM HEPES, 10 mM MgCl2, 100 mM NaCl, 2 mM EGTA, 20 µM 
GDP, pH 8.0, 15 - 35 µg membrane protein (pre-treated as described above), 1.5 mg wheat germ 
agglutinin scintillation proximity assay (WGA SPA) beads (Amersham, Freiburg, Germany), 0.05 - 
0.2 nM GTPγ[35S] (Amersham, Freiburg, Germany), and the test compounds (agonists and/or 
antagonists) at the appropriate concentrations. Non-specific binding was measured in the presence 
of unlabelled GTPγS (Sigma, Buchs, Switzerland) in excess (10 µM). The samples were incubated 
at room temperature for 40 - 60 min (with shaking) before the WGA SPA beads were sedimented 
by centrifugation at 200 g for 10 min at room temperature. The plates were then counted in a 
Packard TopCount (Packard, Zürich, Switzerland). L-Glutamate (L-Glu), DL-2-amino-4-
phosphonobutyric acid (DL-AP4), L-(+)-2-amino-4-phosphonobutyric acid (L-AP4), (RS)-α-
Methylserine-O-phosphate (MSOP), (RS)-α-Cyclopropyl-4-phosphonophenylglycine (CPPG), (2S)-
2-Amino-2-[(1S,2S)-2-carboxycycloprop-1-yl]-3-(xanth-9-yl) propanoic acid (LY341495), and L-
Serine-O-phosphate (L-SOP) were purchased from Tocris (Bristol, UK). (2S)-2-Amino-2-[(1S,2S)-
2-carboxycycloprop-1-yl]-3-[2,7-3H]xanth-9-yl) propanoic acid ([3H]LY341495) was purchased 
from Amersham Biosciences (Freiburg, Germany). 
 
5.11. Second messenger assays 
 
5.11.1. Cyclic AMP assay 
 
Measurements of cyclic AMP (cAMP) accumulation were performed essentially as previously 
described (Flor et al., 1995; Flor et al., 1997) using cAMP SPA direct screening assay system, code 
RPA 559 (Amersham Biosciences, Freiburg, Germany) in CHO cells stably expressing individual 
mGluR subtypes. Briefly, CHO cells expressing mGluR2 and mGluR7 were seeded in 96-well 
plates at a density of 6.5 - 8.5 × 103 cells per well and grown for 1 day until a 40 - 70 % confluent 
layer of cells was obtained. Cells were incubated for 20 min in HBS containing 1 mM IBMX. After 
washing cells with HBS, they were incubated with fresh HBS containing 30 µM forskolin, 1 mM 
IBMX and the test agents for 20 min. The reaction was stopped by aspirating off the drug 
containing medium. The cAMP produced by the cells was released by adding 1 % solution of 
dodecyltrimethylammonium bromide per well and the samples were shaken at room temperature for 
5 min. Then the immunoreagent solution containing equal volumes of [125I]cAMP tracer, antiserum 
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and SPA anti-rabbit reagent in lysis buffer was placed in a final volume of 200 µl per well. A 
standard curve was constructed in the range of 0.2 - 25.6 pmol/well of cAMP for each plate. The 
samples were incubated at room temperature for 15 - 20 hours before the SPA beads were 
sedimented by centrifugation at 900 rpm for 6 min at room temperature. The plates were then 
counted in a Packard TopCount (Packard Instrument Company, Meriden, U.S.A.). The cAMP levels 
of the test wells were calculated relative to the standard curve. 
 
5.11.2. Measurement of [3H] Inositol Phosphate Formation 
 
Clonal cell lines expressing hmGluR1b or hmGluR5a receptors were seeded in 24-well tissue 
culture plates. Cells were labeled to equilibrium with 2 µCi/ml myo-[3H]inositol (American 
Radiolabeled Chemicals, St. Louis, MO) for 20 h in Dulbecco’s modified Eagle’s medium, washed 
twice in Krebs-Henseleit buffer (Sigma, Buchs, Switzerland), and incubated for 30 min at room 
temperature. Subsequently, cells were washed in buffer containing 10 mM LiCl and incubated in 
the same medium for 20 min at 37°C. After aspiration of medium, compounds were added to 
triplicate wells in the presence or in the absence of L-Glutamate in buffer containing 10 mM LiCl. 
Inositol phosphate formation was measured essentially as described by Seuwen et al., (1988). In 
brief, the reaction was stopped after an incubation of 20 min at 37°C by aspiration of the medium 
and lysis of the cells with 0.75 ml of ice-cold 10 mM formic acid (pH 3). After 30 min the extract 
was diluted into 2 ml of 5 mM NH3 solution (yielding a final pH of 8 - 9) and applied to a column 
containing DOWEX-1 × 8 (Fluka, Buchs, Switzerland). After flow-through of the extract, columns 
were washed with 10 ml of H2O and 6 ml of 5 mM sodium tetraborate, 60 mM sodium formate, 
respectively. Inositol monophosphates were eluted with 6 ml of 100 mM formic acid, 200 mM 
anmonium formate. The eluted samples were counted 7 h after addition of 15 ml Irgasave Plus 
scintillation cocktail (Packard, Zürich, Switzerland). Each data point represents triplicate 
measurements expressed as mean ± S.E.M. 
 
5.11.3. Calcium measurements 
 
Functional activation of ionotrophic glutamate receptors was assayed by means of fluorometric 
measurements of changes in intracellular free calcium concentration [Ca2+]i as described by Flor et 
al., (1996) based on the calcium sensitive dye fura-2 (Grynkiewicz et al., 1985). Briefly, cells were 
grown on glass cover slips. On the day of the assay, the cover slips were incubated at room 
temperature for 60 min in a HEPES buffered saline (Life Technologies/GibcoBRL, Basel, 
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Switzerland) containing 10 µg/ml fura-2/AM (Molecular Probes Inc., Eugene, OR, USA), 5 µl/ml 
DMSO and 0.5 % pluronic (Molecular Probes Inc., Eugene, OR, USA). Glass cover slips carrying 
the dye loaded cells were mounted into a perfused cuvette in a fluorescence spectrophotometer 
(Hitachi F - 4500; Hitachi, Tokyo, Japan). Changes in [Ca2+]i were monitored by measuring the 
ratio of fura-2 fluorescence (510 nm) excited alternatively (1.6 Hz) at 340 and 380 nm. Thus, an 
increase of the fluorescent response ratio F340/F380 corresponds to an increase in  [Ca2+]i 
(Grynkiewicz et al., 1985). To test specificity of agonist activation of NMDA or AMPA receptors, 
D-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid, CGP40116 (provided by Novartis Pharma 
AG) or 6-cyano-7-nitroquinoxaline-2, 3-dione, CNQX (Tocris Cookson Ltd., Bristol, UK) was 
applied respectively. 
 
5.12. [3H]LY341495 binding assay  
 
This radioligand binding assay was done by Yamamoto R, as follows. Membrane fractions of CHO 
cells stably expressing mGluR7a (see above) were diluted in assay buffer (10 mM KH2PO4, 100 
mM KBr, pH 7.6), homogenized briefly using a Polytron and incubated for 10 min at 30 °C. Assay-
mixtures were prepared in 96-well microtiter plates. The composition of the assay mixtures in a 
final volume of 200 µl per well was as follows: 10 mM KH2PO4, 100 mM KBr, pH 7.6, 50 µg pre-
treated membrane protein, 1.5 mg WGA SPA beads, 10 nM (2S)-2-Amino-2-[(1S,2S)-2-
carboxycycloprop-1-yl]-3-[2,7-3H]xanth-9-yl) propanoic acid, [3H]LY341495 (Amersham 
Biosciences, Freiburg, Germany) and the test compounds at the appropriate concentrations. Non-
specific binding was measured in the presence of 1 mM L-SOP (Tocris, Bristol, UK). The samples 
were incubated for 60 min at room temperature (with shaking), before being counted in a Packard 
TopCount (Packard, Zürich, Switzerland). Data were analyzed using nonlinear regression in the 
GraphPad Prism program (Graphpad Software Inc., San Diego, USA.). IC50s were converted into 
Kis using the Cheng and Prusoff equation (Cheng and Prusoff, 1973). 
 
5.13. Electron microscopy studies  
 
Wild-type mice (10 – 12 weeks, C57BL/6 genetic background) were injected either vehicle or 6 
mg/kg AMN082 as described above (see Materials and Methods 5.2.). One hour later, these mice 
were anesthetized by pentobarbital (60 mg/kg, i.p.) and then perfused transcardially with PB 
containing 4 % paraformaldehyde, 0.05 % glutaraldehyde, and 0.2 % picric acid. The brains were 
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cut into 50 µm-thick frontal sections on a vibratome (Microslicer, Dosaka, Kyoto, Japan). The 
sections were placed in PB containing 25 % sucrose and 10 % glycerol for 30 minutes, and then 
freeze–thawed in liquid nitrogen. The sections were immunostained with the affinity – purified 
antibody (courtesy of Ryuichi Shigemoto, National Institute for Physiological Sciences, Okazaki, 
Japan) against mGluR7a or mGluR7b as follows. They were incubated sequentially with (1) 20% 
normal goat serum (NGS) diluted in 50 mM Tris buffer (TB) containing 0.9% NaCl [Tris-buffered 
saline (TBS)] for 1 hr, (2) incubation buffer (PBS containing 0.1 % BSA) for 10 minutes, 2 times, 
(3) 1.0 µg/ml rabbit anti-mGluR7a IgG or 1.0 µg/ml rabbit anti-mGluR7b IgG in incubation buffer 
at 4 °C for 24 hours, (4) goat anti-rabbit (Fab fragment, diluted 1:100) coupled to 0.8 nm gold 
(Nanoprobes, Stony Brook, NY) made up in incubation buffer. After washes in incubation buffer 
and PBS, sections were washed in double-distilled water, followed by silver enhancement of the 
gold particles with an HQ Silver kit (Nanoprobes) for 5 - 10 min. After washes in PB, the sections 
were treated with 1% OsO4 in PB for 40 min, washed in PB and double-distilled water, and then 
contrasted in 1% uranyl acetate for 25 min. They were dehydrated in a series of ethanol and 
propylene oxide and flat embedded in epoxy resin (Durcupan ACM; Fluka, Buchs, Switzerland). 
After polymerization, sections were cut at 50 - 75 nm thickness by Ryuichi Shigemoto and Sachiko 
Yamada, using an ultramicrotome (Reichert Ultracut E; Leica, Vienna, Austria). Ultrathin sections 
were analyzed in an EM208S transmission electron microscope (Philips, Netherlands) with Kodak 
electron microscope films 4489 (Kodak, USA). These analyses were conducted in a blind trial. 
Then films were developed into papers (Fujiboro WP FM2; Fuji photo film, Tokyo, Japan) using 
with FSP-1435 B/W paper processor (FC Manufacturing, Itami, Japan) and 450M-D classic 
enlarger (fujimoto photo industrial, Osaka, Japan). 
 
5.14. Statistical analysis  
 
Data are reported as means ± S.E.M. Values of mGluR7-/- mice or AMN082 injected mice were 
compared with those of mGluR7+/+ mice or vehicle injected mice respectively by using the two-
tailed Student’s t test. Otherwise, Dunnett’s t test was used as mentioned in detail in each figure 
legends. The level of significance was set at p < 0.05. 
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6. Results 
 
6.1. Neurophysiological analysis of mGluR7 deficient mice 
 
6.1.1. Analysis of transcript levels of stress-related genes 
 
In an attempt to address the physiological basis of the behavioral phenotype of mGluR7-/- mice, 
which showed reduced anxiety- and depression-like features, gene expression levels associated with 
the stress system of the brain were analyzed. The genes chosen were those encoding GR, MR, CRF, 
CRF receptor type 1 (CRFR1) and the 5-HT1A receptor. Fig. 6.1.1. shows expression levels of 
mGluR7 and these five stress-related genes in the hippocampus, the hypothalamus and the 
prefrontal cortex of mGluR7+/+ and mGluR7-/- male mice. As expected, there was no detectable 
level of mGluR7 mRNA either in the hippocampus, in the hypothalamus or in the prefrontal cortex 
of mGluR7-/- mice. In the hippocampus, mGluR7-/- mice showed an increased GR level compared to 
mGluR7+/+ mice, which was highly significant in p.m. sacrificed animals (p = 0.007; Fig. 6.1.1.D) 
but did not reach statistical significance in a.m. sacrificed animals (p = 0.093; Fig. 6.1.1. A). 5-HT1A 
receptor (5-HT1AR) levels were increased in the hippocampus and in the prefrontal cortex of both 
a.m. (p = 0.002 and 0.016, respectively) and p.m. (p = 0.002 and 0.038, respectively) sacrificed 
mGluR7-/- mice, when compared to mGluR7+/+ mice (Fig. 6.1.1.A, C, D, F). The elevated levels of 
5-HT1A receptor mRNA in the hypothalamus of mGluR7-/- mice did not quite reach the level of 
statistical significance (p = 0.055 and 0.064; for a.m. and p.m. sacrificed animals respectively; Fig. 
6.1.1.B, E). Expression levels of MR, CRF, and CRFR1 remained unchanged in the hippocampus, 
the hypothalamus and the prefrontal cortex between the two genotypes. 
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Figure 6.1.1. Transcript levels related to the stress system in the brain (Mitsukawa et al., 2006). 
Relative transcript levels of mGluR7 and stress-related genes in the hippocampus (A, D), the hypothalamus 
(B, E) and the prefrontal cortex (C, F) of male mGluR7+/+ and mGluR7-/- mice. Sample collection was 
performed in the morning (7:00 - 8:00 a.m.; A, B, C) and in the afternoon (4:00 - 6:00 p.m.; D, E, F). All 
values are normalized to the expression level of the reference gene 18S rRNA. The mRNA levels of 
mGluR7+/+ mice are set arbitrarily to the expression level of 1.0. Expression levels in mGluR7-/- mice (filled 
columns) are shown relative to mGluR7+/+ animals (opened columns). The data, displayed as means ± S.E.M., 
are the average values of two independent determinations (A, B, D, E) or the average of the triplicate 
experiment (C, F). Each bar represents a group of 7 - 12 animals. Statistical analysis was done by Student’s t 
test. ** p < 0.01, * p < 0.05; groups that differed significantly from mGluR7+/+ mice. 
 
 
6.1.2. Basal conditions of stress hormone levels 
 
Basal levels of serum corticosterone and ACTH concentrations were measured in mGluR7+/+ and 
mGluR7-/- mice. These analyses were conducted in both male and female mice. Although mGluR7-/- 
male mice showed lower levels of both corticosterone and ACTH, especially in the morning (Fig. 
6.1.2.), this did not reach statistical significance presumably due to the large variation between 
animals. mGluR7-/- female mice also showed lower levels of these stress hormones and the ACTH 
concentration of p.m. sacrificed mGluR7-/- mice was significantly decreased, compared to that of 
mGluR7+/+ mice (Fig. 6.1.3.). Body weight and adrenal gland weight of mGluR7-/- mice were 
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somewhat lower than those of mGluR7+/+ mice; however adrenal gland weight normalized to body 
weight showed no difference between mGluR7+/+ and mGluR7-/- mice (Table 6.1.; provided by 
Conrad Gentsch).  
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Figure 6.1.2. Basal serum stress hormone levels in male mice (Mitsukawa et al., 2006). 
Basal plasma corticosterone (A, B) and ACTH (C, D) concentrations of male mGluR7+/+ and mGluR7-/- mice 
(n = 8 - 10 per group). Sample collection was performed in the morning (7:00 - 8:00 a.m.; A, C) and in the 
afternoon (5:00 - 6:00 p.m.; B, D). All bars represent means ± S.E.M. Statistical analysis was done by 
Student’s t test. No mGluR7-/- group showed significant difference when compared with the mGluR7+/+ 
group (p > 0.05). 
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Figure 6.1.3. Basal serum stress hormone levels in female mice. 
Basal plasma corticosterone (A, B) and ACTH (C, D) concentrations of female mGluR7+/+ and mGluR7-/- 
mice (n = 8 - 10 per group). Sample collection was performed in the morning (7:00 - 8:00 a.m.; A, C) and in 
the afternoon (5:00 - 6:00 p.m.; B, D). All bars represent means ± S.E.M. Statistical analysis was done by 
Student’s t test. No mGluR7-/- group showed significant difference when compared with the mGluR7+/+ 
group (p > 0.05). 
 
Adrenal gland 
weight  
genotype Body weight 
(g) 
mg mg/10 g BW 
n 
+/+ 30.3 ± 0.6 3.2 ± 0.3 1.0 ± 0.1 8 male 
-/- 26.6 ± 1.1 2.7 ± 0.3 1.0 ± 0.1 8 
+/+ 24.4 ± 0.8 5.7 ± 0.5 2.4 ± 0.2 10 female 
-/- 22.5 ± 0.7 5.6 ± 0.5 2.5 ± 0.2 10 
 
 
Table 6.1. Body weight and adrenal gland weight of mGluR7+/+ and mGluR7-/- mice (Mitsukawa et al., 
2006). 
Results represent means ± S.E.M. BW; body weight . This table was provided by Conrad Gentsch. 
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6.1.3. Effects of swim stress on stress hormone levels 
 
In a next experiment, the levels of corticosterone and ACTH in response to swim stress were tested 
with mGluR7+/+ and mGluR7-/- mice (10 male animals each). When blood samples were taken 
between 8:00 and 11:00 a.m., mGluR7-/- mice showed lower levels of corticosterone (Fig. 6.1.4.A) 
and ACTH (Fig. 6.1.4.D) compared to mGluR7+/+ mice (corticosterone; 9.55 ± 1.86 ng/ml vs. 27.57 
± 6.86 ng/ml, p = 0.029, ACTH; 33.65 ± 3.00 ng/ml vs. 75.55 ± 18.78 ng/ml, p = 0.054). These 
basal levels without swim stress showed less animal to animal variation than data of Fig. 6.1.2. 
Immediately after swim stress, mGluR7-/- mice showed an increase in the levels of corticosterone 
(Fig. 6.1.4.B) and ACTH (Fig. 6.1.4.E) comparable to mGluR7+/+ mice, and there was no difference 
between the two genotypes. In addition, at the point of 90 min after swim stress, the stress-induced 
increase of corticosterone and ACTH levels were recovered at least partially in both genotypes (Fig. 
6.1.4.C, F), however the levels of both stress hormones in mGluR7-/- mice showed a trend lower 
than in mGluR7+/+ mice, which may lead to the suggestion that mGluR7-/- mice may affect the 
recovery of the hormonal system from the stress, although these differences did not reach statistical 
significance. 
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Figure 6.1.4. Basal and swim stress-modified levels of serum stress hormone levels in male mice 
(Mitsukawa et al., 2006). 
Baseline and swim stress-modified levels of plasma corticosterone (A, B, C) and ACTH (D, E, F) 
concentrations of male mGluR7+/+ and mGluR7-/- mice (n = 9 - 10 per group). The duration of swim stress 
was 6 min. Sample collection was performed between 8:00 and 11:00 a.m.. All bars represent means ± 
S.E.M. Statistical analysis was done by Student’s t test. * p < 0.05; groups that differed significantly from 
mGluR7+/+ mice. 
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6.1.4. Dexamethasone suppression test 
 
The levels of plasma corticosterone and ACTH were also examined when mice were injected with 
the synthetic glucocorticoid, dexamethasone, to investigate the GR-mediated negative feedback 
system of the HPA axis. Fig. 6.1.5. illustrates plasma concentrations of corticosterone and ACTH in 
mGluR7+/+ and mGluR7-/- mice injected with saline, 0.03 or 0.1 mg/kg dexamethasone 
subcutaneously (SC). Plasma corticosterone concentrations of vehicle-treated mGluR7+/+ and 
mGluR7-/- mice were not different at afternoon time points (2:00 – 3:00 p.m.; Fig. 6.1.5.A).  
Administration of 0.03 mg/kg dexamethasone reduced plasma corticosterone level in mGluR7-/- 
mice (Fig. 6.1.5.B) and there was a significant difference between these two genotypes (p = 0.041). 
The injection of 0.1 mg/kg dexamethasone showed a suppression of corticosterone levels both in 
mGluR7+/+ and mGluR7-/- mice (Fig. 6.1.5.C) compared to vehicle-treated animals of both 
genotypes (Fig. 6.1.5.A) and there was no significant difference anymore between the two 
genotypes. On the other hand, at the same time points (2:00 – 3:00 p.m.), the plasma ACTH level of 
vehicle-treated mGluR7-/- mice was significantly less than that of mGluR7+/+ mice (Fig. 6.1.5.D; p = 
0.022). Administration of 0.03 mg/kg dexamethasone resulted in reduced plasma ACTH levels in 
mGluR7-/- and mGluR7+/+ mice (Fig. 6.1.5.E); ACTH was lower in mGluR7-/- mice than in 
mGluR7+/+ mice, although this was not quite statistically significant (p = 0.061). With the injection 
of 0.1 mg/kg dexamethasone, both mGluR7+/+ and mGluR7-/- mice showed suppressed ACTH 
levels (Fig. 6.1.5.F) and there was no significant difference between the genotypes. 
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Figure 6.1.5. Basal and swim stress-modified levels of serum stress hormone levels in male mice 
(Mitsukawa et al., 2006). 
Baseline and dexamethasone-inhibited corticosterone (A, B, C) and ACTH (D, E, F) concentrations of male 
mGluR7+/+ and mGluR7-/- mice (n = 8 - 10 per group). Sample collection was performed between 2:00 and 
3:00 p.m., 6 hr after subcutaneous (SC) injection of dexamethasone. All bars represent means ± S.E.M. 
Statistical analysis was done by Student’s t test. * p < 0.05; groups that differed significantly from 
mGluR7+/+ mice. 
 
 
6.1.5. Expression levels of BDNF transcript and protein 
 
Next, the investigation as to whether BDNF levels are changed in mGluR7-/- mice was conducted 
by using RT-PCR and ELISA assays for mRNA and protein level determination, respectively. 
Sample collection was done at the same time point as Fig.6.1.1. In a.m. sacrificed animals, there 
was no difference in either mRNA or protein level at a preliminary experiment between mGluR7+/+ 
and mGluR7-/- mice (data not shown). In p.m. sacrificed animals (4:00 - 6:00 p.m.), there was no 
difference in BDNF mRNA either in the hippocampus, in the hypothalamus, or in the prefrontal 
cortex between mGluR7+/+ and mGluR7-/- mice (Fig. 6.1.6.A). However, mGluR7-/- mice showed a 
significantly increased level of BDNF protein in the hippocampus as compared to mGluR7+/+ mice 
(p = 0.022), although the prefrontal cortex showed no difference (Fig. 6.1.6.B) which demonstrates 
that there is a level of regional specificity to the increases in BDNF. This result in the hippocampus 
was confirmed by repeating the experiment independently with 9 - 12 mice per group in tissue that 
was freshly dissected (Fig. 6.1.6.C). The same differences between the two genotypes (p = 0.001) 
were obtained, which demonstrates that mGluR7-/- mice show a 20 - 25 % increase of BDNF 
protein level in the hippocampus as compared to mGluR7+/+ animals. 
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Figure 6.1.6. Basal and swim stress-modified levels of serum stress hormone levels in male mice 
(Mitsukawa et al., 2006). 
Relative BDNF transcript levels in the hippocampus, the hypothalamus and the prefrontal cortex (A) and 
protein levels in the hippocampus (B, C) and the prefrontal cortex (B) of male mGluR7+/+ and mGluR7-/- 
mice (n = 8 - 12 per group). Sample collection was performed in the afternoon (4:00 - 6:00 p.m.) and various 
regions were dissected either from frozen/freshly thawed brains (A, B) or fresh brains (C). The relative 
transcript levels are normalized to the expression level of the reference gene 18S rRNA. The mRNA data, 
displayed as means ± S.E.M., are the average value of two independent determinations in the hippocampus 
and the hypothalamus, or the average value of the triplicate experiment in the prefrontal cortex (n = 8 - 11 
animals per group). Expression levels in mGluR7-/- mice (filled columns) are shown relative to those in 
mGluR7+/+ mice (opened columns) that are set arbitrarily to the expression level of 1.0. Statistical analysis 
was done by Student’s t test. ** p < 0.01, * p < 0.05; groups that differed significantly from mGluR7+/+ mice. 
Hypoth.; hypothalamus, Prefrontal Cx.; prefrontal cortex 
 
 
 
6.2. Characterization of the first selective mGluR7 agonist, AMN082 
 
6.2.1. Effect of AMN082 on cloned mGluR7 
 
As described and demonstrated above, cumulative data has supported an important physiological 
role of mGluR7. However, there was no previously known pharmacological tool selective for 
mGluR7. It was therefore an aim in this thesis to identify and characterize mGluR7 selective 
pharmacological tools. Here, I would like to disclose the characterization of the first selective 
mGluR7 agonist, N,N'-dibenzhydryl-ethane-1,2-diamine dihydrochloride, AMN082. This 
compound was originally obtained a patent by Ciba-Geigy AG with its property of alleviation of 
breathing difficulties (Karl et al., 1982) and was therefore in chemical libraries at Novartis (Costa et 
al., 2002). In the year 2001 – 2002, approximately 200,000 compounds were screened with 
mGluR7-expressing cell lines by high throughput random screening of chemical libraries at 
Novartis. Among those, AMN082 was initially identified as a compound with similar responses to 
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L-AP4. The chemical structure of AMN082 (Fig. 6.2.1.B) is completely unrelated to the known 
mGluR7 ligands which are all derived from the L-glutamate back-bone such as L-AP4 (Fig. 6.2.1.A; 
reviewed in Yang, 2005)  
 
 
Figure 6.2.1. Chemical structures of L-AP4 and AMN082. 
L-AP4
H2O3P COOH
NH2
AMN082
N
H
N
H
• 2 HCl
A B
 
o investigate stimulating effects of AMN082, stimulation of GTPγ[35S] binding was measured. 
 
T
This stimulation of GTPγ[35S] binding is widely used to assess functional activity of G protein 
coupled receptors (Lazareno and Birdsall, 1993; Kowal et al., 1998; Urwyler et al., 2001). The 
novel compound, AMN082, itself induced the stimulation of GTPγ[35S] binding significantly in 
CHO cells stably expressing human mGluR7b (hmGluR7b), without any orthosteric ligands (Fig. 
6.2.2.A). In addition, when tested in the presence of the lower concentration (200 µM) and the 
higher concentration (saturating concentration; 4 mM) of DL-AP4, GTPγ[35S] binding was 
markedly enhanced by AMN082 (Fig. 6.2.2.A). However, no such activity with AMN082 was seen 
in CHO cells stably expressing hmGluR2 (Fig. 6.2.2.B). This was also the case in CHO cells stably 
expressing rat mGluR7a (rmGluR7a) or rmGluR2 (Fig. 6.2.2.C, D). AMN082 itself stimulated 
GTPγ[35S] binding comparable to or even greater than the saturating activity of DL- AP4. 
 
 40
        
B
D
ba
sa
l
M 
L-G
lu
µ4 
M 
L-G
lu
µ
10
0 M 
AM
N0
82
µ
+ 1
 M
 A
MN
08
2
µ
+ 1
0 
M 
AM
N0
82
µ
+ 1
  
M 
AM
N0
82
µ
+ 1
0  
0
5000
10000
15000
rmGluR2
G
TP
γ [3
5 S
] b
in
di
ng
 (c
pm
)
ba
sa
l 4
M 
DL
-A
P
µ
20
0 
4
4 m
M 
DL
-A
P
M 
AM
N0
82
µ3 M
 A
MN
08
2
µ
10
 M
 A
MN
08
2
µ3 M
 A
MN
08
2
µ
10
 M
 A
MN
08
2
µ3 M
 A
MN
08
2
µ
10
 
0
5000
10000
15000
20000
rmGluR7a
G
TP
γ [3
5 S
] b
in
di
ng
 (c
pm
)
ba
sa
l
M 
L-G
lu
µ2 M
 L-
Gl
u
µ
50
 M 
AM
N0
82
µ3 M
 A
MN
08
2
µ
10
 M
 A
MN
08
2
µ3 M
 A
MN
08
2
µ
10
 M
 A
MN
08
2
µ3 M
 A
MN
08
2
µ
10
 
0
5000
10000
hmGluR2
G
TP
γ [3
5 S
] b
in
di
ng
 (c
pm
)
2 µM
L-Glu
50 µM
L-Glu
G
TP
γ [3
5 S
] b
in
di
ng
 (c
pm
)
G
TP
γ [3
5 S
] b
in
di
ng
 (c
pm
)
A
ba
sa
l 4
M 
DL
-A
P
µ
20
0 
4
4 m
M 
DL
-A
P
M 
AM
N0
82
µ3 
M 
AM
N0
82
µ
10
 M
 A
MN
08
2
µ3 
M 
AM
N0
82
µ
10
 M
 A
MN
08
2
µ3 
M 
AM
N0
82
µ
10
 
0
5000
10000
15000
20000
hmGluR7b
G
TP
γ [3
5 S
] b
in
di
ng
 (c
pm
) 200 µMDL-AP4
4 mM
DL-AP4
** **
G
TP
γ [3
5 S
] b
in
di
ng
 (c
pm
)
G
TP
γ [3
5 S
] b
in
di
ng
 (c
pm
)
G
TP
γ [3
5 S
] b
in
di
ng
 (c
pm
)
C
200 µM
DL-AP4
4 mM
DL-AP4
**
**
** **
4 µM
L-Glu
100 µM
L-Glu
Figure 6.2.2. mGluR7-selectivity of AMN082 in GTPγ[35S] binding assays. 
Robust stimulation of both mGluR7 splice variants was demonstrated by GTPγ[35S] binding (A, C), although 
no stimulation of GTPγ[35S] binding by AMN082 was detected in CHO cells stably expressing both human 
(h)- and rat (r)- mGluR2 (B, D). In A and C, All six groups that contained AMN082 showed significantly 
increased level of GTPγ[35S] binding compared with the respective controls (p < 0.01 for each of those six 
groups; Dunnett’s t test; symbols are not shown). **, More than additive increases (p < 0.01) vs. the 
combined effect of 200 µM DL- AP4 or 4 mM DL- AP4 and the respective concentration of AMN082, 
respectively; Dunnett’s t test. 
 
 
As shown in Fig.6.2.3.A, the saturating concentration of 4 mM DL-AP4 produced approximately 
50 % inhibition of forscolin-induced cAMP accumulation in CHO cells stably expressing the 
hmGluR7b. AMN082 elicited a concentration-dependent inhibition of forskolin-stimulated cAMP 
accumulation in hmGluR7b-expressing CHO cells (Fig. 6.2.3.C, EC50 = 64 ± 32 nM), comparable 
in efficacy to a saturating concentration of the orthosteric group III mGluR agonist, 4mM DL-AP4 
(Fig. 6.2.3.C, dotted line). Up to 3 µM, there was no effect of AMN082 in the same assay 
conducted with hmGluR2-expressing CHO cells (Fig. 6.2.3.B). Again the same can be said in CHO 
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cells stably expressing rmGluR7a or rmGluR2 (Fig. 6.2.3.D - F), as follows. The saturating 
concentration of 4 mM DL-AP4 produced approximately 50 % inhibition of forskolin-stimulated 
cAMP accumulation in CHO cells stably expressing rmGluR7a. AMN082 was found to potently 
inhibit forskolin-stimulated cAMP accumulation in rmGluR7a-expressing cells, producing 30 to 
50 % inhibition at a maximally effective concentration of 3 µM and an EC50 value of 94 ± 48 nM 
(Fig. 6.2.3.D, F). In contrast, AMN082 showed no inhibition of forskolin-stimulated cAMP 
accumulation in rmGluR2-expressing cells at concentrations of up to 3 µM (Fig. 6.2.3.E). 
 
A hmGluR7b hmGluR2B C hmGluR7b
 
Figure 6.2.3. Agonist effects of AMN082 in CHO cells stably expressing mGluR7 but not mGluR2. 
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Forskolin (30 µM) stimulated cAMP levels (taken as control) and AMN082 inhibited this forskolin-
F) in a 
.2.2. Selectivity profiling of AMN082 
he activity of AMN082 was addressed at all eight known mGluRs and at three selected ionotropic 
stimulated cAMP accumulation in CHO cells expressing either hmGluR7b (A, C) or rmGluR7a (D, 
concentration dependent manner, although AMN082 showed no effects on CHO-mGluR2 cells (B, E). 
Results are expressed as % of control and were pooled from at least four measurements obtained in two 
independent experiments, and expressed as means with S.E.M. **, p < 0.01 vs. control; Dunnett’s t test. 
 
 
 
6
 
T
receptors. Fig.6.2.4. shows the effects of AMN082 on group II and III mGluRs except mGluR2 and 
mGluR7 which were already shown in Fig 6.2.2. While GTPγ[35S] binding was enhanced by 
AMN082 on hmGluR7b- and rmGluR7a-expressing membranes (Fig 6.2.2.), little or no stimulating 
effect was seen on membranes from hmGluR3-, hmGluR4-, hmGluR6-, and hmGluR8a-expressing 
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cells, although the overall signal quality on hmGluR8 was relatively small.  No GTPγ[35S] binding 
stimulation in untransfected CHO cells was confirmed.  
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Figure 6.2.4. Effects of AMN082 across group II and III mGluR subtypes. 
AMN082 had little or no effect on the agonist-induced stimulation of GTPγ[35S] binding via mGluR3, 
mGluR4, mGluR6 or mGluR8a expressed in CHO cells, nor in untransfected CHO cells. The data shown are 
taken from a typical experiment, performed in triplicate, and expressed as mean counts per minute (cpm) 
values with S.E.M. 
 
Measurements of phosphoinositol (PI) hydrolysis were done to address whether AMN082 activates 
group I mGluR subtypes (Fig.6.2.5.). There were no effects of AMN082 in the absence and in the 
presence of the lower and the maximal concentration of L-glutamate at either hmGluR1b- or 
hmGluR5a-expressing cells, suggesting that AMN082 has neither agonist-like, positive modulatory 
nor negative modulatory activities at these cells. 
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Figure 6.2.5. Effects of AMN082 on group I mGluRs. 
AMN082 had no effect on mGluR1b (A) nor mGluR5a (B) in the absence and in the presence of a low (100 
µM for mGluR1b and 2 µM for mGluR5a) and a high (1 mM for mGluR1b and 30 µM for mGluR5a) 
concentration of L-Glu.  IP accumulation was measured in CHO cells stably expressed mGluR1b or 
mGluR5a that were incubated with AMN082 in the absence and in the presence of L-Glu.  Data represent the 
mean ± S.E.M. of at least three independent experiments and all values were normalized to the control 
stimulation of respective concentrations (1 mM for mGluR1b, and 30 µM for mGluR5a, set to 100%) 
 
 
Furthermore, the characterization was extended to ionotropic receptors. To address functional 
agonist and antagonist activity of AMN082 at cloned human NMDARs (hNMDARs), cytoplasmic 
calcium determinations were employed with stable cell lines transfected with hNMDAR1a/2A and 
hNMDA1a/2B subunit combinations (Fig.6.2.6.). In the presence and in the absence of L-glutamate, 
AMN082 showed no effect on the cytoplasmic calcium ion concentrations in these cell lines, even 
when it was also pre-applied. The representative calcium signal wave is shown in Fig. 6.2.6.A. D-
cycloserine (DCS), a partial agonist at the strychnine-insensitive glycine-recognition site on the 
NMDAR complex, increased calcium signal amplitude only in hNMDAR1a/2A transfected cells 
(Fig.6.2.6.B), but not in hNMDAR1a/2B transfected cells (Fig.6.2.6.C). In both cell lines 
transfected hNMDAR1a/2A and hNMDAR1a/2B subunit combinations, a competitive NMDAR 
antagonist D-(E)-2-amino-4-methyl-5-phosphono-3-pentenoic acid, CGP40116 (Fagg et al., 1990) 
completely inhibited L-glutamate induced response.   
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Figure 6.2.6. Effects of AMN082 on NMDA-type ionotrophic glutamate receptors. 
Elevation of cytoplasmic calcium ion concentrations, [Ca2+]i, in Ltk- cells expressing cloned hNMDA 
receptors (subunit combination 1a/2A and 1a/2B). (A) Increase in the fluorescent response ratio F340/F380 
corresponds to an elevation in [Ca2+]i. Two consecutive calcium measurements are shown: application of L-
Glu alone, followed by co-application of L-Glu and AMN082. The duration of the applications is indicated 
by bars (black: 3 µM L-glutamate; grey: 3 µM AMN082). (B, C) Each column represents calcium signals 
(mean values ± S.E.M.) of three independent experiments in either NMDAR1a/2A (B) or NMDA1a/2B (C) 
transfected cells. AMN082 had no effects on the cytoplasmic calcium ion concentrations, [Ca2+]i, in the 
absence and in the presence of low and high concentrations of L-Glu. L-Glu induced response was inhibited 
completely by the competitive NMDA antagonist, CGP 40116. 100 µM D-cycloserine (DCS) increased 3 
µM L-Glu induced calcium signal in NMDA1a/2A transfected cells (B). The response of saturated 
concentration of L-Glu (20 µM for NMDA1a/2A and 3 µM for NMDA1a/2B) was taken as control and set to 
100%.  #; Groups in which drugs were pre- and co-applied with L-Glu. ** p < 0.005; Groups that differed 
significantly from 3 µM L-Glu (Dunnett’s t test).  
 
 
 
In addition, the profile of AMN082 was characterized against stable cell lines expressing human 
AMPA receptor GluR3 flip splice variant (hGluR3i) by the same method as hNMDARs; 
intracellular calcium measurements (Fig.6.2.7.).  There was no change of calcium signal amplitude 
by AMN082 application either in the presence or in the absence of L-glutamate stimulation.  Pre-
application of AMN082 showed no change, either.  L-glutamate induced response was completely 
inhibited by a selective AMPA receptor antagonist, 6-cyano-7-nitroquinoxaline-2, 3-dione, CNQX 
(Honore et al., 1988). 
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Figure 6.2.7. Effects of AMN082 on AMPA-type ionotrophic glutamate receptors. 
Elevation of cytoplasmic calcium ion concentrations, [Ca2+]i, in HEK cells expressing cloned hAMPA 
receptor, GluR3 flip splice variant (GluR3i). (A) Increase in the fluorescent response ratio F340/F380 
corresponds to an elevation in [Ca2+]i. Two consecutive calcium measurements are shown: application of L-
Glu alone, followed by co-application of L-Glu and AMN082. The duration of the applications is indicated 
by bars (black: 20 µM L-Glu; grey: 3 µM AMN082). (B) Each column represents calcium signals (mean 
values ± S.E.M.) of three independent experiments. AMN082 had no effects on [Ca2+]i, in the absence and in 
the presence of low (20 µM) and high (80 µM) concentrations of L-Glu. L-Glu induced response was 
inhibited completely by the AMPA receptor antagonist, CNQX.  The response of 80 µM L-Glu was taken as 
control and set to 100%.  #; Groups in which drugs were pre- and co-applied with L-Glu. 
 
 
Table 6.2.1. shows the summary of the effects of AMN082 on all eight mGluRs and on three 
ionotropic GluRs. The activating effect of AMN082 (up to 10 µM) was selectively seen at 
mGluR7a and -7b with large efficacies of 70 - 140 % (relative to maximal DL-AP4 effects), 
although AMN082 elicited little or no stimulating effects at mGluR1b, mGluR2-, mGluR3-, 
mGluR4-, mGluR5a, mGluR6-, mGluR8a-, NMDAR1a/2A-, NMDAR1a/2B-, or GluR3i-
expressing cells. 
mGluR7a           GTPγ[35S] binding             105 – 140 %; 3 µM, 10 µM n.e.; ≤ 10 µM 
mGluR7b           GTPγ[35S] binding             70 – 90 %; 3 µM, 10 µM n.e.; ≤ 10 µM 
mGluR1b PI hydrolysis  5 – 15 %; 1 – 10 µM n.e.; ≤ 10 µM 
mGluR2  GTPγ[35S] binding    n.e.; ≤ 10 µM n.e.; ≤ 10 µM 
mGluR3  GTPγ[35S] binding    n.e.; ≤ 10 µM n.e.; ≤ 10 µM 
mGluR4   GTPγ[35S] binding   6 – 18 %; 1 – 10 µM n.e.; ≤ 10 µM 
mGluR5a  PI hydrolysis n.e.; ≤ 3 µM n.e.; ≤ 3 µM 
mGluR6  GTPγ[35S] binding   n.e.; ≤ 10 µM n.e.; ≤ 10 µM 
mGluR8a  GTPγ[35S] binding    10 – 20 %; 1 – 10 µM n.e.; ≤ 10 µM 
NMDA1a/2A  Cytoplasmic Ca2+       n.e.; ≤ 10 µM n.e.; ≤ 10 µM 
NMDA1a/2B  Cytoplasmic Ca2+       n.e.; ≤ 10 µM n.e.; ≤ 10 µM 
GluR3 (flip)    Cytoplasmic Ca2+     n.e.; ≤ 10 µM n.e.; ≤ 10 µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Receptor 
subtype 
 Functional assay % Inhibition induced by 
AMN082; concentration 
% Activation induced by 
AMN082; concentration  
 
Table 6.2.1. Summary table of mGluR7-selectivity of AMN082 across glutamate receptor subtypes 
(Mitsukawa et al., 2005). 
Data from 2 - 4 independent experiments were averaged; n.e., no effect. 
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6.2.3. AMN082 directly interacts with the heptahelical region of mGluR7 
 
Concentration-response curves for AMN082, DL-AP4 and L-glutamate are compared in Fig. 6.2.8. 
AMN082 is far more potent than the orthosteric ligands, DL-AP4 and L-glutamate; the EC50-values 
(95 % confidence intervals) are 260 nM (200; 360), 540 µM (440; 670) and 700 µM (580; 850), 
respectively.                       
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Figure 6.2.8. Concentration-response curves for AMN082, DL-AP4 and L-Glu (Mitsukawa et al., 2005). 
At least three independent experiments were pooled and all values were normalized to the control stimulation 
of 8 mM L-Glu (set to 100%). Means with S.E.M. are shown. 
 
 
Stimulation of GTPγ[35S] binding was performed to evaluate further the pharmacological properties 
and mechanism of action of AMN082. AMN082 (3 µM) produced 167 ± 8 % stimulation relative to 
the maximal agonist activity of L-glutamate (set to 100 %, Fig. 6.2.9.). The stimulating effects of 
AMN082 were almost additive with those of L-glutamate and DL-AP4 (238 ± 11 % and 336 ± 19 %, 
respectively), while DL-AP4 plus L-glutamate (both at maximally active concentrations) produced a 
smaller stimulation than DL-AP4 alone (133 ± 4 % versus 216 ± 12 %, Fig. 6.2.9.).  
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Figure 6.2.9. Additive effects of AMN082 to orthosteric ligands on membranes from CHO-mGluR7b  cells 
(Mitsukawa et al., 2005). 
The indicated concentrations of AMN082, DL-AP4, and L-Glu were applied alone and in combination with 
each other in GTPγ[35S] binding experiments. Three independent experiments were combined and means 
with S.E.M. are shown. Statistics symbols are shown for co-application of drugs as follows: **, P < 0.01 vs. 
8 mM L-Glu (control); ##, P < 0.01 vs. 5 mM DL-AP4; Dunnett’s t test. 
 
 
Next, the group III mGluR-selective antagonists MSOP and CPPG (Thomas et al., 1996; Toms et 
al., 1996) were tested against concentration-response curves of AMN082 conducted in the absence 
(Fig. 6.2.10.A) and presence of submaximal DL-AP4 (Fig. 6.2.10.B): the DL-AP4 component was 
completely abolished by the antagonists (Fig. 6.2.10.B) while there was no inhibition of the 
AMN082-stimulated GTPγ[35S] binding (Fig. 6.2.10.A).  
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Figure 6.2.10. Lack of the effects of competitive group III mGluR antagonists on AMN082 stimulated 
GTPγ[35S] binding. 
Concentration-response curves of AMN082 in the absence (A) or in the presence (B) of 0.2 mM DL-AP4 
with and without CPPG or MSOP, using GTPγ[35S] binding on CHO-mGluR7b membranes; mean data ± 
S.E.M. from a single representative experiment (n = 3). 
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To analyze a potential co-operativity between L-glutamate site ligands and AMN082, 
concentration-response curves for AMN082 at different fixed concentrations of L-glutamate (Fig. 
6.2.11.A), and inversely, curves for L-glutamate versus fixed concentrations of AMN082 (Fig. 
6.2.11.B) were conducted. The EC50 of AMN082 varied between 140 and 290 nM with largely 
overlapping 95 % confidence intervals (Fig. 6.2.11.A and Table 6.2.2.). Similarly, the EC50 of L-
glutamate was consistently between 640 µM and 830 µM, irrespective of the added concentration of 
AMN082 (Fig. 6.2.11.B and Table 6.2.2.).  
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Figure 6.2.11. AMN082 and orthosteric L-glutamate (L-Glu) site ligands have little, if any, effect on each 
other’s potency. 
(A) Concentration-response curves for AMN082 in the absence and in the presence of different 
concentrations of L-Glu. Three independent experiments were pooled and all values were normalized to the 
control stimulation of 8 mM L-Glu (set to 100%); means with S.E.M. are shown. (B) Concentration-response 
curves for L-Glu in the absence and in the presence of different concentrations of AMN082. Four 
independent experiments were pooled and all values were normalized to control (as above). 
 
 
                                    
AMN082    EC50 of L-Glu       Maximal effect relative  
  (95 %  CI)           to 8 mM L-Glu control      
   0           260 (160; 450)     207 (187; 227)              3
  30          290 (130; 650)            232 (199; 264)                3 
 100         210 (110; 390)            202 (181; 223)                3 
 300         210 (80; 570)              224 (191; 257)                3 
1000        140 (70; 250)              263 (244; 281)                3 
3000        150 (80; 270)              276 (259; 293)                3 
L-Glu      EC50 of AMN082     Maximal effect relative  
  (95 %  CI)           to 8 mM L-Glu control      
n   
µM nM %
   0           700 (580; 850)        107 (100; 114)              3
  10          640 (410; 1000)          128 (110; 145)                3 
  30          780 (460; 1320)          163 (134; 191)                3 
 100         830 (400; 1760)          200 (155; 246)                3 
 300         830 (590; 1170)          214 (195; 233)                3 
1000        830 (350; 1980)          248 (194; 302)                3 
%
n 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
nM µM 
Table 6.2.2. Summary table of Fig.6.2.11 (Mitsukawa et al., 2005). 
The calculated parameters from at least three separate experiments, parts of which are shown in Fig.6.2.11., 
indicated that L-Glu or AMN082 had little effect on AMN082 or L-Glu potency, respectively; CI, 95 % 
confidence interval. 
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To address whether binding of AMN082 to mGluR7 affects the binding affinity of ligands for the 
et al., 2000) binding was analyzed from membranes prepared from CHO cells stably expressing 
showed no displacement of this radioligand; in contrast, 10 mM of L-AP4, L-glutamate, or L-SOP 
4
i
4
4
L-glutamate + 3 µM AMN082, 524 µM (436; 631). 
ere performed in the absence (open symbols) and in the 
L-glutamate site, displacement of 10 nM [3H]LY341495 (a competitive mGluR antagonist; Wright 
rmGluR7a (This was done by Rina Yamamoto; Master thesis in 2005 at School of Allied Health 
Sciences, Graduate School of Medicine, Osaka University, Osaka, Japan); up to 30 µM AMN082 
abolished 100 % of specific binding (Fig.6.2.12.; provided by Rina Yamamoto). Moreover, 
[3H]LY341495 displacement curves were conducted with L-SOP, L-AP  and L-glutamate, each in 
the absence and presence of 3 µM AMN082. The addition of AMN082 induced only a minor left-
shift of each of the three curves; the calculated K s with 95 % confidence intervals (in brackets in 
µM) were as follows: L-SOP, 45 µM (39; 50); L-SOP + 3 µM AMN082, 29 µM (24; 35); L-AP , 
193 µM (165; 224); L-AP  + 3 µM AMN082, 176 µM (144; 216); L-glutamate, 624 µM (446; 870); 
 
Figure 6.2.12. Displacement experiments for [3H]LY341495 binding to rmGluR7a membranes with 
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A B
AMN082 and known L-glutamate site ligands . 
Assays with known L-glutamate site ligands w
presence (closed symbols) of 3 µM AMN082. (A) Effects of AMN082 or unlabelled-LY341495 alone or the 
combination of those are presented. In contrast to LY341495, AMN082 did not displace binding at 
concentrations of up to 30 µM. (B) Effects of L-SOP, L-AP4 and L-Glu are presented. All values 
represent % of total specific bound, and were pooled from at least six measurements obtained in three 
independent experiments, and expressed as means with S.E.M. Non-specific binding, defined by the amount 
bound in the presence of 1 mM L-SOP, was subtracted from all values. This figure was provided by Rina 
Yamamoto (Master thesis in 2005 at School of Allied Health Sciences, Graduate School of Medicine, Osaka 
University, Osaka, Japan). 
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Furthermore, to localize the binding site of AMN082 to one discrete region of the mGluR7 protein, 
GTPγ[35S] binding assays were conducted with constructs of wild-type mGluR7b and mGluR6 as 
well as two chimeras: the mGluR6/7b construct contains the N-terminal extracellular region of 
mGluR6 and the C-terminal portion of mGluR7b comprising the entire transmembrane region; 
mGluR7/6 is the reverse chimera (See Materials and Methods 5.9.; Fig. 6.2.13.). The activity of 
AMN082 on mGluR6/7b and mGluR7/6 chimeras was very similar to wild-type mGluR7b and 
mGluR6, respectively: AMN082 stimulated mGluR7b and mGluR6/7b to 150 - 200 % relative to 
the maximal effect of DL-AP4, but AMN082 produced only minor effects on mGluR6- and 
mGluR7/6-expressing membranes (10 - 25 % relative to maximal DL-AP4 stimulation); Fig. 
6.2.13.A - D. It is interesting to note that the stimulating effects of AMN082 and DL-AP4 were 
more than additive on those mGluR7 expressing membranes but not on mGluR6/7b membranes 
(Fig. 6.2.13.A, C). 
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Figure 6.2.13. AMN082 activates G protein signaling via a binding site in the transmembrane region of 
mGluR7 (Mitsukawa et al., 2005). 
Effect of AMN082 on GTPγ[35S] binding in the absence and presence of DL-AP4 using membranes from 
CHO-C4 cells stably expressing mGluR7b (A) or mGluR6 (B). (C, D) The effect of AMN082 on 
mGluR6/7b (C) and mGluR7/6 (D) chimeric receptor cell membranes is shown. cDNAs were constructed by 
Natacha Stoehr. All bars represent the mean ± S.E.M. of at least three independent experiments, conducted 
with n = 3 - 4, and all values were normalized to the control stimulation of the respective agonist 
concentrations (4 mM DL-AP4 for mGluR7 and mGluR7/6, and 10 µM DL-AP4 for mGluR6 and 
mGluR6/7b). **, significant increases versus maximal DL-AP4 controls (P < 0.01); ##, P < 0.01 vs. additive 
effect of submaximal DL-AP4 (gray bar) and 3 µM AMN082 (black bar); Dunnett’s t test. 
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Concentration-response curves for AMN082 on mGluR6/7b and mGluR7/6 chimeras are compared 
in Fig. 6.2.14. AMN082 has much higher potency and efficacy on mGluR6/7b chimeras (Fig. 
6.2.14.A) than those on mGluR7/6 chimeras (Fig. 6.2.14.B). In addition, initial attempts using 
truncated mutants with deleted extracellular domains were made, owing to Stoehr N and Pescott O, 
but no activation with DL-AP4 or AMN082 was observed; it cannot be ruled out that their translated 
proteins were mis-folded or incorrectly inserted into membranes. 
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Figure 6.2.14. Considerably higher potency and efficacy of AMN082 on mGluR6/7b than on mGluR7/6. 
(A) A concentration-response curve for AMN082 in the GTPγ[35S] binding assay on mGluR6/7b (A) or 
mGluR7/6 (B) chimeric receptor. Both efficacy and potency of AMN082 is much larger in mGluR6/7b 
chimeric receptor. Data represent the mean ± S.E.M. of at least three independent experiments and all values 
were normalized to the control stimulation of respective concentrations (4 mM for mGluR7/6, and 10 µM for 
mGluR6/7b, set to 100%). 
 
 
6.2.4. In vivo activity of AMN082: modulation of stress hormones in an mGluR7-dependent 
fashion 
 
The role of mGluR7 in stress-related behavior is well documented (Cryan et al., 2003; Masugi et al., 
1999; Mitsukawa et al., 2006). Therefore, the effect of oral administration of AMN082 was 
analyzed on serum levels of the stress hormones corticosterone and ACTH. Fig. 6.12.15. shows that 
AMN082 readily passes the blood-brain barrier upon oral administration and increases plasma 
corticosterone in a dose-dependent manner in a wild-type mouse strain (C57BL/6). Next, mGluR7-
deficient mice (mGluR7-/-) and their wild-type littermates (mGluR7+/+) were used. Again, oral 
administration of 6 mg/kg of AMN082 elicited a circa 200 % increase of plasma corticosterone in 
mGluR7+/+ animals, but no such rise was observed in mGluR7-/- mice (Fig. 6.12.15.B). Similarly, 
blood-levels of ACTH were also increased to 200 %, one hour following oral AMN082 
administration, in wild-type animals, but not in mGluR7-deficient mice (Fig. 6.12.15.C). 
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Figure 6.2.15. AMN082 induces stress hormone increases in an mGluR7-dependent fashion (Mitsukawa 
et al., 2005). 
Vehicle or AMN082 were administered to mice orally (p.o.) and one hour later mice were decapitated and 
the blood was collected. Plasma corticosterone and ACTH levels were measured with radioimmunoassay kits. 
(A) Effect of 1 and 6 mg/kg AMN082 (p.o.) on plasma corticosterone level in naive C57BL/6 mice. (B) 6 
mg/kg AMN082 (p.o.) increased plasma corticosterone level approximately to 200 % of vehicle control in 
mGluR7+/+ mice, but not in mGluR7-/- mice. (C) AMN082 increased plasma ACTH level in mGluR7+/+ mice 
to the same relative level as shown for corticosterone, but no change was observed in mGluR7-/- mice. Data 
were normalized to each vehicle control and represent the mean ± S.E.M. from 9 - 13 independent mice per 
group. **, p < 0.01 vs. vehicle control; two-way ANOVA followed by Fisher’s post hoc test. 
 
 
6.3. Internalization of mGluR7 
 
It has recently been demonstrated that mGluR7 is internalized in response to L-AP4 (Pelkey et al., 
2005). It was therefore interesting to investigate whether AMN082 induces internalization of 
mGluR7. To test this possibility, immunoelectron microscopic studies were performed with 
antibodies against mGluR7a or mGluR7b (Shigemoto et al., 1997) in hippocampal sections of 
mouse brain slices treated orally with either vehicle or 6 mg/kg AMN082. In vehicle-treated 
sections, using pre-embedding immunogold labeling, mGluR7a (Fig. 6.3.1.A, left panel) and 
mGluR7b (Fig. 6.3.1.B, left panel) immunoreactivity consistently localized within active zones in 
presynaptic membranes making asymmetric synapses in the hippocampal CA3 as previously 
reported (Shigemoto et al, 1997; Pelkey et al., 2005). In contrast to these sections from vehicle-
treated animals, immunogold particles for both mGluR7a (Fig. 6.3.1.A, right panel) and mGluR7b 
(Fig. 6.3.1.B, right panel) also often appeared far from the active zone deep within presynaptic areas 
making asymmetric synapses within the hippocampal CA3 of brain sections from AMN082-treated 
animals. To test specificity of the procedures for electron microscopy, the primary antibody was 
omitted. It was confirmed that under this condition, no selective labeling was observed (data not 
shown). In addition, some sections were proceeded with immunocytohistochemical methods 
without silver intensification. With these methods, no metal particles were detected (data not 
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shown). The observation of immunogold particles for mGluR7a and mGluR7b deep within mossy 
fiber boutons in AMN082-treated brain sections strongly suggests that mGluR7a and mGluR7b do 
indeed undergo internalization.   
 
 
Figure 6.3.1. Representative electron micrographs showing mGluR7a and mGluR7b localization. 
mGluR7a mGluR7b mGluR7bmGluR7a
Pre-embedding immunogold labeling for mGluR7a and mGluR7b in CA3 after oral administration of 6
t at the 
ig. 6.3.2. shows quantitative assessment from electron micrographs, representatives of which are 
but also the number of synapses which have internalized mGluR7a and/or mGluR7b. 
vehicle + AMN082A B vehicle + AMN082
 
mg/kg AMN082 (A, B: right panel) or vehicle (A, B: left panel) is shown. Open arrowheads poin
synaptic cleft with post-synaptic density (asymmetrical synapses) and closed arrowheads point at 
immunoparticles indicating internalized mGluR7a (A) and mGluR7b (B). Scale bars are 0.3 µm.  
 
 
F
shown in Fig. 6.3.1. For quantification, numbers of immunoparticles were counted which are 
localized within active zones and also those which located far from active zones deep within 
presynaptic areas. The following criteria for an active zone in electron micrographs were used; 
presynaptic areas within twice the length of synaptic cleft from the presynaptic membrane are 
regarded as an active zone. It was observed that acute 6 mg/kg AMN082 treatment induced 
mGluR7a internalization to 15.1 ± 1.7 % above the control level (vehicle-treated groups; 5.6 ± 
1.1 %); Fig. 6.3.2.A. Similarly, mGluR7b was also internalized by AMN082 (12.5 ± 1.3 %) 
significantly more than the control level (vehicle-treated groups; 6.5 ± 0.1 %); Fig. 6.3.2.A. In 
addition, to test whether AMN082 changed the ratio of synapses which showed internalization of 
mGluR7, the number of synaptic profiles was evaluated based on whether they had internalized 
mGluR7 (Fig. 6.3.2.B). This approach showed that AMN082 indeed increased the ratio of synaptic 
profiles showing internalization of mGluR7a and mGluR7b compared to vehicle-treated controls 
(32.2 ± 0.3 % vs. 16.4 ± 3.1 % and 35.1 ± 3.3 % vs.22.4 ± 0.7 %, respectively). Therefore, acute 
AMN082 oral injection increased not only the total quantity of internalized mGluR7a and mGluR7b 
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Figure 6.3.2. AMN082 increases internalization of mGluR7a and mGluR7b. 
Quantitative analysis of electron micrographs from three independent treated mice per group (vehicle cont
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7. Discussion 
 
7.1. Neurophysiological consequences of mGluR7 deficiency 
 
The present study demonstrated that selective ablation of the group III mGluR subtype 7 is 
associated with specific changes in molecular targets that participate in the stress response and in 
psychopathological states. Thus, the findings here suggest that drugs acting at mGluR7 may provide 
new approaches to stress-related psychiatric disorders such as depression and anxiety. 
mGluR7 ablation leads to increased levels of GR and the 5-HT1AR in the hippocampus without 
altering MR, CRF or CRF1 mRNA levels. These transcripts were chosen for analysis because of 
their key regulatory role in the mammalian stress system (De Kloet et al, 2005). The finding that 
only GR and 5-HT1A receptor transcript levels are altered in mGluR7-deficient mice implies a 
selective effect on the feedback system in the HPA-axis. The expression levels of both of these 
genes have previously been shown to be altered by stress, glucocorticoid and antidepressants 
(Hugin-Flores et al., 2004; Karandrea et al., 2002; Lopez et al., 1998; Okugawa et al., 1999; Seckl 
and Fink, 1992). Furthermore, mice with functional downregulation/ablation of these two receptors 
have altered behaviors in models of anxiety and depression (Boyle et al., 2005; Toth, 2003; Urani 
and Gass, 2003). The HPA axis activity is controlled by a feedback mechanism triggered mainly 
through the stimulation of GRs located in the cerebral cortex, the hippocampus, and the 
hypothalamus (Diorio et al., 1993; Feldman and Weidenfeld, 1999; Magarinos et al., 1987; 
Mizoguchi et al., 2003), and a reduced GR expression and function has been proposed to contribute 
to HPA axis alterations in depression (Holsboer and Barden, 1996; Pariante and Miller, 2001; 
Webster et al., 2002). It is also known that the expression and function of the 5-HT1A receptor is 
regulated by glucocorticoids and GRs (Andrews et al., 2004; Chalmers et al., 1994; Froger et al., 
2004; Hery et al., 2000; Laaris et al., 1995; Ou et al., 2001). Taken together these data suggest that 
there is a selective dysregulation of the stress response in mGluR7-/- mice which is opposite to that 
seen in some human psychopathological states, e.g. in some depressed patients. 
Glutamatergic neurotransmission has long been implicated as an important regulator of the stress 
response (van den Pol et al, 1990; Brann, 1995). mGluRs in particular appear to play a crucial role 
in mediating neuroendocrine responses. Specifically, the nonselective mGluR agonist (1S,3R)-1-
aminocyclopentane-1,3-dicarboxylate (ACPD), when administered i.c.v., induced a significant 
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increase in plasma corticosterone (Lang and Ajmal, 1995). Whereas, an involvement of group I and 
possibly group II mGluRs has been reported (Johnson et al, 2001; Bradbury et al, 2003; 
Scaccianoce et al, 2003), it has also been demonstrated that i.c.v. administration of the nonselective 
group III mGluR agonists L-AP4 and L-SOP activates the HPA axis (Johnson et al, 2001). The 
current data showing both altered corticosterone levels and feedback regulation in mGluR7-/- mice 
suggest that mGluR7, at least in part, may modulate the increase in stress hormones induced by 
group III mGluR agonists. The mechanism underlying this increase is currently unclear. However, 
Johnson et al (2001), based on an earlier model of Tasker et al (1998), suggested that as group III 
mGluRs regulate the activity of GABA interneurones in the hypothalamus (Schrader and Tasker, 
1997), agonists, such as L-AP4 and L-SOP, might act by decreasing L-glutamate release from the 
hippocampal–hypothalamic tract. Thus, there would be a decreased tone driving GABAergic 
interneurones and a disinhibition on corticotrophin releasing factor (CRF)-containing 
paraventricular nucleus (PVN) neurons of the hypothalamus. Alternatively, it has been speculated 
that group III agonists might be acting directly on presynaptic terminals of the GABAergic 
interneurones and activate hetero-autoreceptors and thus group III mGluR stimulation could directly 
limit the degree of inhibitory tone that is on the PVN cells (Johnson et al., 2001; Tasker et al., 1998). 
Both scenarios might explain how the absence of mGluR7 leads to a state of neuroendocrine 
dysfunction as has been seen in the present studies which may subsequently induce an altered 
response in stress-related behaviors.  
It is important to note that there are many brain regions other than the hippocampus, the 
hypothalamus and the prefrontal cortex, which contribute to stress-related pathology and future 
studies should focus on whether mGluR7 plays a role in regulating stress-relevant genes in 
structures such as the amygdala, dorsal raphe nucleus, and locus coeruleus.  
To further examine the potential functional consequences of the changes in stress-related gene 
expression baseline and stress-induced concentrations of corticosterone and ACTH were assessed in 
mGluR7-/- mice. There was a strong trend toward a lower basal corticosterone and ACTH level 
which suggests that mice lacking mGluR7 have abnormal concentrations of circulating 
glucocorticoids. However, both genotypes responded equally, in terms of neuroendocrine activation, 
to swim stress insults which resulted in a marked increase in corticosterone and ACTH levels. It is 
possible that a ceiling response was observed and that a differential effect might be observed if a 
less severe stress were applied. However, the rationale for choosing this stressor was based on the 
fact that mGluR7-/- mice have an altered behavioral response in this model (Cryan et al., 2003). 
To assess whether there is an altered GR-mediated negative feedback, studies with the synthetic 
glucocorticoid dexamethasone were conducted which at low doses acts as a GR agonist (Cole et al., 
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2000; Groenink et al., 2002; Meijer et al., 1998). Plasma corticosterone concentrations of vehicle-
treated mGluR7+/+ and mGluR7-/- mice were not different at afternoon time points (2:00 – 3:00 
p.m.; Fig. 6.1.5.A) in this test. This is probably due to circadian pattern in the levels of circulating 
glucocorticoids. Therefore, this further illustrates that caution needs to be taken regarding the time 
of day that sacrifice of animals is carried out for the assaying of stress hormones. On the other hand, 
the plasma ACTH level of vehicle-treated mGluR7-/- mice was significantly less than that of 
mGluR7+/+ mice (Fig. 6.1.5.D). Difference between ACTH levels and corticosterone levels may 
reflect the different temporal patterns of these stress hormones. Full online analysis of these 
hormones maybe required to discriminate these differences in detail. Mice lacking mGluR7 show a 
clear hypersensitivity to dexamethasone at the lower dose tested (0.03 mg/kg). This suggests that 
there is indeed an altered functional negative feedback of the HPA axis. This enhanced suppression 
is opposite to that seen in many depressed patients who have a blunted hormonal response to 
dexamethasone (Carroll, 1982; Holsboer et al., 1980). This correlates well with the antidepressant-
like response observed in behavioral studies with mGluR7-/- mice (Cryan et al., 2003). Despite its 
historical widespread use in clinical settings there are surprisingly few studies employing the 
dexamethasone suppression test in genetically modified mice (Cryan and Mombereau, 2004). Here 
it has been demonstrated that the dexamethasone suppression test can be a sensitive marker of HPA 
axis dysregulation. Interestingly, although mGluR7-/- mice have a dysregulated HPA axis, these 
alterations occur independently of any gross abnormality in adrenal weight with both genotypes 
having the same relative adrenal weight (Table 6.1.). Increases in relative adrenal weight have been 
observed following chronic stress (Watanabe et al., 1992) and in major depression (Nemeroff et al., 
1992). 
An increase in BDNF protein levels were observed in the hippocampus of mGluR7-/- mice in a 
reproducible fashion, which also correlates well with the antidepressant-like phenotype observed 
behaviorally. Intracerebral ventricular or intrahippocampal administration of BDNF has been shown 
to have an antidepressant-like effect in various animal tests which are often used for assessing 
antidepressant activity (Hoshaw et al., 2005; Shirayama et al., 2002; Siuciak et al., 1997). 
Furthermore, antidepressant medications have been shown to increase BDNF levels in the 
hippocampus (De Foubert et al., 2004; Nibuya et al., 1995; Russo-Neustadt et al., 2004; but see 
Altar et al., 2003; Coppell et al., 2003; Jacobsen and Mork, 2004). Further evidence for a role of 
BDNF in antidepressant action comes from studies using genetically modified mice with impaired 
levels of BDNF or its receptor TrK-B, which are resistant to the behavioral effects of 
antidepressants (Saarelainen et al., 2003). Emerging evidence further suggests that BDNF may play 
a key role in the pathophysiology of stress-related disorders. Lower hippocampal BDNF levels have 
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been found subsequent to various stressors such as prenatal stress (Fumagalli et al., 2004), 
footshock stress (Rasmusson et al., 2002), postnatal stress (MacQueen et al., 2003; Roceri et al., 
2004) and restraint stress (Smith et al., 1995; Vaidya et al., 1997; Xu et al., 2004). Also of interest 
is the fact that intra-hippocampal administration of BDNF protects against stress-induced 
impairments in spatial learning and memory and LTP (Radecki et al., 2005). Mechanisms 
underlying how stress alters BDNF levels and how BDNF modifies behavior are not currently clear 
(Tapia-Arancibia et al., 2004). Interestingly, recent studies have shown that BDNF can have direct 
stimulating effects on the HPA axis suggesting that BDNF could be a stress-responsive intercellular 
messenger since when it is exogenously administered it acts as an essential factor in the activation 
and recruitment of hypothalamic CRF neurons (Givalois et al., 2004). However, the effects of 
chronic BDNF administration on the HPA axis are unknown. It is important to note, that the 
changes in protein levels of BDNF observed in mGluR7-/- mice occur independent of detectable 
changes at the mRNA levels. Reasons for this may in some way be due to the fact that whole tissue 
homogenate may dilute potential effects at the mRNA levels that occur only in specific subregions 
of the hippocampus, however this reasoning is unsatisfactory as it should also apply to regulation at 
the protein level. Moreover, in agreement with our findings, recent studies have also shown very 
disparate results between BDNF mRNA and protein levels in the same tissue following various 
antidepressant manipulations (De Foubert et al., 2004; Jacobsen and Mork, 2004). The reasons for 
such differential responses at mRNA and protein level are currently unclear and warrant further 
investigation. However BDNF is generated as pre-pro-BDNF protein, which is further processed 
until it is secreted as mature homodimeric protein into the extracellular space (reviewed in 
Lessmann et al., 2003) and therefore these processes possibly reflect regulation of BDNF at the 
translational level.  
There has been an upsurge in the use of genetically modified mice to assess depression and anxiety 
related phenotypes (Cryan et al., 2002; Cryan and Mombereau, 2004). However, the majority of 
phenotypic analysis has focused specifically on behavioral readouts, such as immobility in the 
forced swim test, in isolation of other physiological and molecular biomarkers. The current data 
demonstrate the utility of adapting such an approach and exemplify how such analyses can 
complement behavioral studies. This is perhaps even more important for mice which have 
genetically modified levels of target proteins, such as in the case of mGluR7, where there are no 
complementary pharmacological tools available. However, it cannot be ruled out that the changes 
observed here may be secondary to alterations in other circuits, not yet identified, which are directly 
influenced by the null mutation of mGluR7. In conclusion, the current data demonstrate that 
ablation of mGluR7 results in specific changes in key regulators of the HPA axis, namely 5-HT1A 
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receptors, GR, corticosterone, and in altered BDNF levels, in a direction opposite to that found in 
human depression or following chronic stress. These changes correlate with the previously 
identified anti-stress and antidepressant-like behavioral effects observed in mGluR7-/- mice. 
Furthermore, the current data suggest that selective mGluR7 ligands may provide a novel strategy 
for modifying stress-related disorders. 
 
7.2. The first selective mGluR7 agonist  
 
As discussed above, it was very desirable to identify mGluR7-selective ligands. This thesis presents 
the first selective mGluR7 agonist, AMN082. This compound acts via a novel site, is orally active, 
and modulates the in vivo levels of two stress hormones, corticosterone and ACTH in wild-type but 
not in mGluR7-deficient mice substantiating further a role for mGluR7 in stress physiology.   
AMN082 elicits a full agonist response comparable to L-AP4 in the absence of glutamate-site 
ligands, although L-glutamate and DL-AP4 are likely to interact at the same receptor site and the 
activity of the full agonist DL-AP4 appears to be inhibited by the partial agonist L-glutamate (Fig. 
6.2.9.). The current data with chimeric receptors strongly suggests the localization of a novel 
allosteric agonist site within the heptahelical domain of mGluR7. Definitive proof for this allosteric 
site awaits the development of an appropriate radioligand which will enable determination of 
physico-chemical binding characteristics such as Kd, Kon, and Koff. However, the chimeric receptor 
data together with the absence of AMN082 activity at other Gi-coupled mGluRs expressed in 
identical host cells as used for mGluR7 functional studies strongly argues that the agonist activity of 
AMN082 results from a direct compound interaction with the mGluR7 protein. In particular, this 
mGluR7-dependent agonist activity is seen in both the G protein assay (GTPγS binding) and in 
second messenger determinations (cAMP) which drastically reduces the possibility of AMN082 
interacting with downstream components of the intracellular signaling cascades. In GTPγS binding, 
the activities of AMN082 and L-glutamate-site ligands were close to additive using the previously 
described cell line for human mGluR7b (Flor et al., 1995; Flor et al., 1997; Gasparini et al., 1999a; 
Maj et al., 2003) in the presence of a saturating concentration of the orthosteric agonist (Fig. 6.2.2.A 
and Fig.6.2.9.). However, Fig.6.2.2.A showed more than additive increases in the presence of a 
submaximal concentration of DL- AP4. Greater than additive effects of AMN082 and DL-AP4 were 
also observed on membranes from the new human mGluR7b cell line prepared for the present 
chimera studies (Fig. 6.2.13), and although to a lesser extent on rat mGluR7a expressing 
membranes (Fig. 6.2.2.C). In addition, the % activation induced by AMN082 relative to DL-AP4 
differs between the three cell lines. Further studies are required to understand these differences; it 
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may be possible that the mGluR7 receptor number in relation to the expression level of endogenous 
G proteins is quite different between the cell lines; this may potentially mask allosteric potentiation 
in one case but allow it in the other case. It is also unclear at present whether the alternative C-
termini of mGluR7a versus mGluR7b could contribute to these differences. AMN082 was not 
inhibited by competitive glutamate-site antagonists, and neither functional potency nor binding 
affinity of glutamate-site agonists were significantly affected by AMN082 (Fig. 6.2.10 – 6.2.12., 
Table 6.2.2.), strengthening the argument for a site of action different from the glutamate binding 
site. Accordingly, it is proposed that AMN082 binds to the heptahelical region of mGluR7 and 
favors directly the formation of the active receptor state, as postulated also for orthosteric agonists 
by the two-state model of receptor activation (Seifert and Wenzel-Seifert, 2003); orthosteric agonist 
binding seems to be not required for AMN082 interaction with mGluR7. Binding to the 
transmembrane region has also been postulated for the GABAB receptor modulator CGP7930, 
which was found to directly activate the receptor but with low efficacy (Binet et al., 2004). The 
mGluR5-positive modulator 3,3’-difluorobenzaldazine acted as a full agonist on mGluR5 deleted of 
its extracellular domain, but this compound did not act as agonist itself on the non-mutated full-
length receptor (Goudet et al., 2004). A more recent mGluR5 positive modulator, 3-cyano-N-(1,3-
diphenyl-1H-pyrazol-5-yl)benzamide (CDPPB), displays partial agonist activity on wild-type 
mGluR5, and this agonist effect cannot be blocked by orthosteric antagonists (Kinney et al., 2005) 
which is similar to the findings with AMN082. In many ways, AMN082 is also similar to ectopic 
agonists of M1 muscarinic receptors such as 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-
piperidine (AC-42) which shows 50 - 70 % efficacy relative to full agonists (Langmead et al., 2006; 
Spalding et al., 2002); however, the effect of AC-42 is blocked by atropine whereas AMN082 
effects are not inhibited by competitive glutamate antagonists. The present study on AMN082 
provides the first evidence for full agonist activity mediated by the heptahelical domain of a wild-
type family 3 GPCR. 
Heretofore, the synthesis of subtype-selective group III mGluR agonists that significantly penetrate 
the blood-brain barrier had not been successful, presumably because orthosteric receptor activation 
requires compounds with an α-amino acid moiety and a distal ionizable ω-phosphono group which 
makes such molecules too hydrophilic for passing biological membranes. In contrast, the allosteric 
agonist AMN082 is structurally completely unrelated to amino acids. Its physico-chemical 
properties allow oral administration resulting in good penetration of the blood-brain barrier. This 
opens up new drug discovery opportunities for harnessing pharmacological activity at its novel 
binding site.  
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A direct interaction of AMN082 with mGluR7 to elicit physiological efficacy in vivo can be 
assumed since AMN082 has been demonstrated to have direct mGluR7-selective activity in vitro 
and elevate plasma levels of the stress hormones corticosterone and ACTH in an mGluR7-
dependent fashion, i.e. it does not occur in mGluR7-deficient (mGluR7-/-) mice. Six minutes of 
swim stress elevated corticosterone and ACTH in both mGluR7+/+ (wild-type) and mGluR7-/- mice 
to 400 - 600 % demonstrating that mGluR7-deficient mice are capable of rapid and robust stress 
hormone up-regulation just like wild-type mice (Fig.6.1.4.). However, the elevating effect of 
AMN082 on stress hormone levels is only seen in mice carrying the functional mGluR7 gene. L-
glutamate has been implicated as a critical neurotransmitter in the regulation of neuroendocrine 
functions (Brann, 1995; van den Pol et al., 1990). While a component of glutamatergic control of 
neuroendocrine function is clearly ionotropic receptor-mediated (Farah et al., 1991; Yousef et al., 
1994), another component appears to act via the G protein-coupled glutamate receptor family as 
already discussed above. The current data with AMN082 suggest that mGluR7, at least in part, 
modulates the increase in stress hormones. The mechanism underlying this increase is still unclear. 
However as already discussed in 7.1. it might be explained based on the implication by Johnson et 
al., (2001); group III mGluRs would lead to a decreased tone driving GABAergic interneurones in 
the hypothalamus and a disinhibition on CRF-containing PVN neurons of the hypothalamus. 
In conclusion, the present study characterizes the first selective mGluR7 agonist AMN082 which 
acts via an allosteric site unknown before and can serve as an important new tool for further 
studying the role of mGluR7 in stress-related CNS disorders. 
  
7.3. Internalization of mGluR7 and behavioral effects of AMN082 
 
The results from this thesis also show that AMN082 induced internalization of mGluR7 in the 
hippocampal neurons one hour after a single oral administration which is in line with the recent 
report that a group III mGluR agonist L-AP4 caused internalization of mGluR7 (Pelkey et al., 2005). 
This finding could be important for the effects of the compound in vivo since regulated endocytosis 
is central to the functional regulation of membrane receptors.  
As described above, AMN082 showed mGluR7-selective agonistic effects in vitro on membranes 
and also elevated the levels of plasma stress hormones in an mGluR7-dependent fashion. However 
in contrast to these findings and also with the expectation from the mGluR7 knockout and 
knockdown phenotypes, AMN082 has shown anxiolytic-like effects in the SIH and the social 
exploration test one hour after oral administration (unpublished observation; but see Thakker et al., 
2005). This discrepancy may be explained by the finding that mGluR7 is internalized by AMN082. 
 62
In addition, although the increase of internalized mGluR7 by AMN082 is small compared to the 
total numbers of mGluR7 (Fig. 6.3.2.), the stress models described above appear to be sensitive 
enough to this change which is further supported by the observations that 10 – 30 % knockdown of 
mGluR7 showed robust reduction of SIH (unpublished observation; but see Thakker et al., 2005). 
The mechanism for internalization of mGluR7 by agonists remains to be determined. However, 
Lavezzari and her colleagues showed at the 35th Society for Neuroscience annual meeting 
(Lavezzari and Roche; poster No. 32.18.) that mGluR7 was internalized via a non-clathrin mediated 
pathway in response to L-AP4 whereas mGluR1a subtype is known to be internalized via an 
arrestin- and clathrin-dependent pathway (Mundell et al., 2001; Pula et al., 2004). Lavezzari further 
showed that truncated mGluR7 with deleted C terminal tyrosine sites increased internalization, 
which was inhibited by a PKC activator. Moreover, they also showed that PKC inhibitor increased 
internalization of wild-type mGluR7, suggesting that mGluR7 phosphorylation was involved in 
regulating endocytosis. One possible mechanism for internalization of mGluR7 might involve the 
anchoring protein, protein kinase C interacting protein (PICK1). PICK1 is known to interact with a 
PDZ-binding motif located at the C terminus of mGluR7 and bind PKCα (Dev et al., 2001). 
Therefore, it can be hypothesized that PICK1 blocks the mGluR7 internalization, stabilizing 
mGluR7 on the surface through phosphorylation and that mGluR7 agonists change the 
conformation of the receptor causing dissociation or degradation of PICK1, which in turn leads to 
the mGluR7 internalization. 
Together with the observations mentioned in this section, emerging studies have pointed to an 
important role of mGluR7 in stress responses and development of selective mGluR7 ligands allows 
us to progress further towards the elucidation of its role in psychiatric research. In this thesis, an 
anxiolytic-like and stress-resistant phenotype has been shown in both mGluR7 knockout and 
knockdown animals as well as in animals treated with AMN082 which induces internalization of 
mGluR7 using selected animal models; therefore, this thesis provides indirect evidence in favor of 
the use of mGluR7 antagonists as possible therapeutics for stress-related disorders.  
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9. Appendix – Abstract pages of Publications from my thesis work. 
 
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18712-7.  
 
A selective metabotropic glutamate receptor 7 agonist: activation of receptor 
signaling via an allosteric site modulates stress parameters in vivo. 
 
Mitsukawa K, Yamamoto R, Ofner S, Nozulak J, Pescott O, Lukic S, Stoehr N, 
Mombereau C, Kuhn R, McAllister KH, van der Putten H, Cryan JF, Flor PJ. 
 
Neuroscience Research, Novartis Institutes for BioMedical Research, Novartis Pharma AG, 
CH-4002 Basel, Switzerland. 
 
Metabotropic glutamate receptor (mGluR) subtypes (mGluR1 to mGluR8) act as important 
pre- and postsynaptic regulators of neurotransmission in the CNS. These receptors consist of 
two domains, an extracellular region containing the orthosteric agonist site and a 
transmembrane heptahelical domain involved in G protein activation and recognition of 
several recently synthesized pharmacological modulators. The presynaptic receptor mGluR7 
shows the highest evolutionary conservation within the family, but no selective 
pharmacological tool was known. Here we characterize an mGluR7-selective agonist, N,N'-
dibenzhydrylethane-1,2-diamine dihydrochloride (AMN082), which directly activates 
receptor signaling via an allosteric site in the transmembrane domain. At transfected 
mammalian cells expressing mGluR7, AMN082 potently inhibits cAMP accumulation and 
stimulates GTPgammaS binding (EC50-values, 64-290 nM) with agonist efficacies 
comparable with those of L-2-amino-4-phosphonobutyrate (L-AP4) and superior to those of 
L-glutamate. AMN082 (< or = 10 microM) failed to show appreciable activating or 
inhibitory effects at other mGluR subtypes and selected ionotropic GluRs. Chimeric receptor 
studies position the binding site of AMN082 in the transmembrane region of mGluR7, and 
we demonstrate that this allosteric agonist has little, if any, effect on the potency of 
orthosteric ligands. Here we provide evidence for full agonist activity mediated by the 
heptahelical domain of family 3 G protein-coupled receptors (which have mGluR-like 
structure) that may lead to drug development opportunities. Further, AMN082 is orally 
active, penetrates the blood-brain barrier, and elevates the plasma stress hormones 
corticosterone and corticotropin in an mGluR7-dependent fashion. Therefore, AMN082 is a 
valuable tool for unraveling the role of mGluR7 in stress-related CNS disorders. 
 
PMID: 16339898 [PubMed - indexed for MEDLINE]  
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 Neuropsychopharmacology. 2005 Oct 12; [Epub ahead of print] 
 
Metabotropic Glutamate Receptor Subtype 7 Ablation Causes Dysregulation 
of the HPA Axis and Increases Hippocampal BDNF Protein Levels: 
Implications for Stress-Related Psychiatric Disorders. 
 
Mitsukawa K, Mombereau C, Lotscher E, Uzunov DP, van der Putten H, Flor PJ, 
Cryan JF. 
 
1Neuroscience Research, Novartis Institutes for BioMedical Research, Novartis Pharma AG, 
Basel, Switzerland. 
 
Regulation of neurotransmission via group-III metabotropic glutamate receptors (mGluR4, -
6, -7, and -8) has recently been implicated in the pathophysiology of affective disorders, 
such as major depression and anxiety. For instance, mice with a targeted deletion of the gene 
for mGluR7 (mGluR7(-/-)) showed antidepressant and anxiolytic-like effects in a variety of 
stress-related paradigms, including the forced swim stress and the stress-induced 
hyperthermia tests. Deletion of mGluR7 reduces also amygdala- and hippocampus-
dependent conditioned fear and aversion responses. Since the hypothalamic-pituitary-
adrenal (HPA) axis regulates the stress response we investigate whether parameters of the 
HPA axis at the levels of selected mRNA transcripts and endocrine hormones are altered in 
mGluR7-deficient mice. Over all, mGluR7(-/-) mice showed only moderately lower serum 
levels of corticosterone and ACTH compared with mGluR7(+/+) mice. More strikingly 
however, we found strong evidence for upregulated glucocorticoid receptor (GR)-dependent 
feedback suppression of the HPA axis in mice with mGluR7 deficiency: (i) mRNA 
transcripts of GR were significantly upregulated in the hippocampus of mGluR7(-/-) animals, 
(ii) similar increases were seen with 5-HT(1A) receptor transcripts, which are thought to be 
directly controlled by the transcription factor GR and finally (iii) mGluR7(-/-) mice showed 
elevated sensitivity to dexamethasone-induced suppression of serum corticosterone when 
compared with mGluR7(+/+) animals. These results indicate that mGluR7 deficiency causes 
dysregulation of HPA axis parameters, which may account, at least in part, for the 
phenotype of mGluR7(-/-) mice in animal models for anxiety and depression. In addition, 
we present evidence that protein levels of brain-derived neurotrophic factor are also elevated 
in the hippocampus of mGluR7(-/-) mice, which we discuss in the context of the 
antidepressant-like phenotype found in those animals. We conclude that genetic ablation of 
mGluR7 in mice interferes at multiple sites in the neuronal circuitry and molecular pathways 
implicated in affective disorders.Neuropsychopharmacology advance online publication, 12 
October 2005; doi:10.1038/sj.npp.1300926. 
 
PMID: 16237391 [PubMed - as supplied by publisher]  
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